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ABSTRACT
LONGITUDINAL BRAIN TUMOR TRACKING, TUMOR GRADING, AND
PATIENT SURVIVAL PREDICTION USING MRI
Linmin Pei
Old Dominion University, 2020
Director: Dr. Khan M. Iftekharuddin
This work aims to develop novel methods for brain tumor classification, longitudinal
brain tumor tracking, and patient survival prediction. Consequently, this dissertation
proposes three tasks. First, we develop a framework for brain tumor segmentation
prediction in longitudinal multimodal magnetic resonance imaging (mMRI) scans,
comprising two methods: feature fusion and joint label fusion (JLF). The first method
fuses stochastic multi-resolution texture features with tumor cell density features, in order
to obtain tumor segmentation predictions in follow-up scans from a baseline preoperative timepoint. The second method utilizes JLF to combine segmentation labels
obtained from (i) the stochastic texture feature-based and Random Forest (RF)-based
tumor segmentation method; and (ii) another state-of-the-art tumor growth and
segmentation method known as boosted Glioma Image Segmentation and Registration
(GLISTRboost, or GB). With the advantages of feature fusion and label fusion, we
achieve state-of-the-art brain tumor segmentation prediction.
Second, we propose a deep neural network (DNN) learning-based method for brain
tumor type and subtype grading using phenotypic and genotypic data, following the
World Health Organization (WHO) criteria. In addition, the classification method
integrates a cellularity feature which is derived from the morphology of a pathology
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image to improve classification performance. The proposed method achieves state-of-theart performance for tumor grading following the new CNS tumor grading criteria.
Finally, we investigate brain tumor volume segmentation, tumor subtype
classification, and overall patient survival prediction, and then we propose a new contextaware deep learning method, known as the Context Aware Convolutional Neural
Network (CANet). Using the proposed method, we participated in the Multimodal Brain
Tumor Segmentation Challenge 2019 (BraTS 2019) for brain tumor volume segmentation
and overall survival prediction tasks. In addition, we also participated in the RadiologyPathology Challenge 2019 (CPM-RadPath 2019) for Brain Tumor Subtype Classification,
organized by the Medical Image Computing & Computer Assisted Intervention
(MICCAI) Society. The online evaluation results show that the proposed methods offer
competitive performance from their use of state-of-the-art methods in tumor volume
segmentation, promising performance on overall survival prediction, and state-of-the-art
performance on tumor subtype classification. Moreover, our result was ranked second
place in the testing phase of the CPM-RadPath 2019.
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CHAPTER 1
INTRODUCTION
Gliomas in central nervous system (CNS), the most common primary brain
malignancies, originate from glial cells in the brain [1]. In the US, 23 out of 100,000 in
the population have been reported as patients with brain tumors annually, from 20112015 [2]. According to the report, 392,982 cases consisted of 30.9% patients with

Figure 1. Distribution of primary brain and other CNS tumors reported during
2011-2015 [1].
malignant tumors and 69.1% patients with non-malignant tumors [2], as shown in Figure
1.
Prior to 2016, a brain tumor may have been graded as I, II, III, and IV respectively,
based on the growth rate, the presence of definitive tumor margins, and the vascularity,
according to the World Health Organization (WHO)’s 2007 diagnostic schema [3]. In
2016, WHO adapted to a new tumor classification criterion based on both phenotype and
genotype [4]. In general, a patient’s survival period is associated with the tumor grade.
The survival period of a patient with a low-grade tumor is much longer than that of a
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patient with a high-grade tumor. According to the report, from 2011-2015, for patients
with malignant tumors, the estimated five- and ten- year relative survival rates were
35.0% and 29.3%, respectively [2]. Glioblastoma multiforme (GBM), originating from
glial cells and growing by infiltrating surround tissues, is the most common and a highly
aggressive type of glioma. The median of the survival period for a patient with GBM still
remains at 12-16 months, even though there have been many treatment advancements [5].
Less than 4% of treated patients with GBM are alive after five years [5-7]. The short
survival period of patients with GBM is not only because of the rapid tumor growth, but
is also due to the tumor’s invasion to surrounding brain tissues [8]. Early and proper
detection of the tumor grade may result in a good prognosis [9].
To achieve a proper prognosis, treatment planning, and follow-up to the patients,
accurate detection, and segmentation of brain tumor are critical. Manual tumor
segmentation by radiologists is very tedious, time consuming, and prone to human error
[10]. Consequently, computer-aided brain tumor analysis is desired. In a clinic, several
image modalities are used for tumor diagnosis, such as computerized tomography (CT),
magnetic resonance imaging (MRI), digital pathology image (DPI), etc. CT is used for
brain tumor detection in its early stages [11]. In its later stages, a structural MRI is widely
used for brain tumor analysis, especially for tumor detection and segmentation [1, 12-17].
In the literature, many methods have been proposed to detect and segment brain tumors,
such as the active contours-based and atlas-based methods. However, performances of
tumor segmentation using atlas-based methods are suffering from the quality of their
image registration. To overcome this issue, brain tumor segmentation is treated as a
classification problem. Traditional machine learning classifiers, such as K-nearest
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neighbor (KNN), support vector machine (SVM), and random forest (RF), are generally
used. As we know, effective and robust feature extraction is the prerequisite for
traditional machine learning based brain tumor segmentation methods. In recent years,
with the success of deep learning in many fields, such as computer vision, speech
recognition, etc., deep learning-based methods have also been applied to medical imaging
processing, including brain tumor detection, segmentation, grading, etc.
Diffuse low-grade gliomas (LGG) and intermediate-grade gliomas are infiltrative
brain neoplasms which include the histological classes Astrocytoma,
Oligodendrogliomas, Oligoastrocytomas, and World Health Organization (WHO) grade
II and III neoplasms. High-grade gliomas are mainly Glioblastoma (WHO grade IV).
Although LGG patients have a longer survival period than those with HGG, the LGGs
have been found to typically progress to secondary GBMs with time, and they cause
eventual death [9]. Tracking longitudinal brain tumor changes over time is critical for
treatment management. Tracking is not only related to accurate tumor volume
segmentation, but it also reveals information about tumor development over time.
Moreover, similar to brain tumor classification, tumor tracking may be useful for patient
survival prediction. Finally, even though there are a few studies on longitudinal brain
tumor tracking in the literature, there is still a lack of robust methods.
This dissertation proposes a novel framework for longitudinal brain tracking, a new
tumor grading following the new WHO tumor classification criterion, and a robust deep
learning architecture for brain tumor segmentation, tumor subtype classification, and
overall patient survival prediction.
1.1 Problem Statement
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The topics mentioned above require efficient commuter-aided brain tumor analysis
and abnormal tumor tissue segmentation methods. Even though there has been a plethora
of techniques on brain tumor analysis and segmentation proposed in the literature,
computer-aided brain tumor analysis is still a challenging task due to multiple factors.
First, brain tumors can have an unpredictable appearance, infiltration to surrounding
tissue, intensity heterogeneity, size, shape, and location variation [18]. Second, tumors
have different degrees of aggressiveness, variable prognosis, and various heterogeneous
histology [1]. Third, intensity gradients between adjacent structures can be obscured due
to tumor penetration or bias field artifacts [12]. Lastly, MR images may be acquired
following different protocols in clinical trials [19].
Among the brain tumor analysis tasks, accurate tumor detection and volume
segmentation are very important for tumor assessment and prognosis. The brain tumor
analysis methods are generally categorized in two groups: traditional feature-based
machine learning methods (such as K-nearest neighbors [20], support vector machine
[21], random forest [22], etc.) and more recent deep neural network-based methods. For
traditional machine learning-based methods, feature extraction is a challenging task.
In general, LGGs are found to typically progress to HGGs, and to eventual death [9].
Longitudinal brain tumor tracking may be accomplished in at least two ways: a) via
image-based tumor volume segmentation, and b) via computational modeling for tumor
growth. As mentioned before, image-based tumor volume segmentation remains
challenging because of imaging artifacts, the variety of image acquisition protocol, and
tumor complex characteristics. Computational tumor growth modeling may be
categorized as a microscopic model or a macroscopic model, according to the observation
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scale. The macroscopic model, which refers to the reaction-diffusion formalism, is widely
used in studies in the literature, because this model considers both microscopic
proliferation and macroscopic diffusion. Tumor growth modeling is difficult because of
two reasons: a) mass effect happens when the tumors invade and push the surrounding
tumor [23, 24], and b) tumors grow at different rates in different types of brain tissues.
For example, tumors have a faster growth rate in white matter (WM) than in gray matter
(GM) [25].
As mentioned in the previous section, the WHO CNS tumor classification guideline
changed in 2016. Prior to 2016, tumor classification was mainly based on histologic
appearance in pathologic slides [3]. Specifically, tumors were classified according to
microscopic similarities with different putative cells of origin and differentiation level
[4]. The histological features of mitotic activity, microvascular proliferation, and necrosis
are used when grading diffuse glioma. However, since using only histopathology data for
tumor grading is no longer accurate and efficient, a new CNS brain tumor grade
classification standard was released by the WHO in 2016 [4]. The new tumor
classification standard requires both phenotype and proteomics information. The most
common proteomics information has isocitrate dehydrogenase (IDH), X1p/19q
codeletion, Alpha thalassemia/mental retardation syndrome X-linked (ATRX), and O6methylguanine-DNA methyl-transferase (MGMT). Since the new tumor classification
criteria were released, there have been few studies in the literature that follow the revised
tumor grading guidelines.
Recently, deep learning methods have attracted huge attention because of the success
in computer vision, pattern recognition, speech recognition, and medical imaging
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processing. Although deep learning-based methods for brain tumor analysis have been an
active area of research in recent years, relevant tasks, such as tumor segmentation,
classification, and overall survival prediction, have mostly been studied individually,
ignoring the underlying relationship among these critical analysis tasks. There is a need
for developing deep learning methods that consider tumor segmentation, tumor subtype
classification, and patient survival prediction as interdependent tasks. Consequently, the
overall aim of this dissertation is to develop a longitudinal brain tumor tracking model
that will help brain tumor diagnosis and classification, as well as patient survivability
prediction.
1.2 Proposed Work and Contributions
This dissertation proposes novel methods for longitudinal brain tumor volume
segmentation and tracking using multimodal MRI, a tumor subtype grading that uses a
deep learning-based method, and tumor classification and survival prediction that uses a
deep learning Context Aware-based Convolutional Neural Network (CANet). It follows
the new WHO tumor classification guideline using structural MRI, and patient survival
prediction is completed by using both structural MRI and clinical data. Consequently, our
first dissertation goal is to improve longitudinal brain tumor tracking by integrating tumor
segmentation and tumor growth modeling using multimodal magnetic resonance imaging
(mMRI) scans. This comprises two methods: feature fusion and joint label fusion (JLF).
The first method fuses stochastic multi-resolution texture features with tumor cell density
features to obtain tumor segmentation predictions in follow-up timepoints, using data
from a baseline pre-operative timepoint. The second method utilizes JLF to combine
segmentation labels obtained from (i) the stochastic texture feature-based and the

7
Random Forest (RF)-based tumor segmentation method and (ii) another state-of-the-art
tumor growth and segmentation method, known as boosted Glioma Image
Segmentation and Registration (GLISTRboost, or GB).
The overall novelty of this work is two-fold: a) tumor cell density is used as a novel
feature to obtain tumor growth segmentation prediction for a prior successful stochastic
multiresolution RF-based segmentation method, and b) it obtains improved tumor
segmentation performance of another successful tumor segmentation tool, GB, by fusing
labels obtained from the tumor segmentation using a RF-based method.
The second goal of the dissertation is to perform brain tumor grading by analyzing
phenotype and proteomics information, using deep learning. This dissertation proposes a
joint analysis of histopathology and proteomics patient data using DNN for brain tumor
grade type and subtype classification, following the new WHO tumor grade criteria. The
work utilizes digital pathology images and four pieces of proteomics information (IDH,
X1p/19q, ATRX, and MGMT) to obtain improved tumor classification accuracy. The
contribution has two parts: 1) development of a deep learning-based method for tumor
grading by utilizing phenotype and proteomics information, and 2) integration of
cellularity obtained from digital pathology image (DPI) to improve tumor grading
accuracy.
Our final goal in this study is to build a robust deep learning architecture suitable for
multiple tumor analysis tasks, including brain tumor segmentation, tumor subtype
classification, and overall survival prediction. This dissertation proposes a context-aware
deep learning method known as the Context Aware Neural Network (CANet). We offer
three contributions, as follows: First, we propose a context-aware deep learning-based
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method for brain tumor segmentation. Second, we utilize a hybrid method for overall
survival prediction, which integrates the deep learning and traditional machine learning
methods. Finally, although the new WHO tumor classification criteria indicate the use of
both pathology images and proteomics information along with MRI, the proposed method
is effective in tumor classification using structural MRI data only. A summary of the
dissertation goals and contributions is listed in Table 1.
We have several peer reviewed publications resulting from the dissertation
contributions, as follow: The research finding related to Dissertation Goal 1 is published
in the 2015 IEEE International Conference on Bioinformatics and Biomedicine (BIBM)
[15], Conference of Medical Imaging 2017: Computer-Aided Diagnosis [14], and Journal
of Biomedical Signal Processing and Control (BSPC) [13]. The research findings related
to Dissertation Goal 2 are under review by the Journal of Medical Image Analysis (MIA).
Finally, the overall contributions of the Dissertation Goal 3 result were accepted as a
conference paper in the Society of Photo-Optical Instrumentation Engineers (SPIE)
Medical Imaging, and an expanded version of this Goal 3 is currently under review by the
journal Scientific Reports – Nature. Moreover, we participated the Computational
Precision Medicine: Radiology-Pathology Challenge on Brain Tumor Classification 2019
(CPM-RadPath) [26], also known as National Institute Health (NIH) Computational
Precision Medicine 2019 Challenge, for the proposed methods of our Dissertation Goal 3.
Our result is ranked in second place in the testing phase [27].
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Table 1. Summary of proposed contribution in the dissertation.
Research Goal
1

2

3

Topic
Improve longitudinal brain
tumor tracking by
integrating tumor
segmentation and tumor
growth modeling

Contributions
Introduction of tumor cell
density obtained from tumor
growth model as novel feature
to tumor segmentation
prediction, and use joint label
fusion to improve tumor
segmentation
Obtain brain tumor grading
Development of tumor grading
by analyzing phenotypic and
by following new WHO tumor
proteomic information
criteria using a deep learningbased method
Build a robust model for
multiple brain tumor
analysis tasks using deep
neural network

Development of context-aware
deep learning for tumor
segmentation, tumor subtype
classification, and overall
survival prediction.

1.3 Organization of the Dissertation
The rest of the dissertation is organized as follows. Chapter 2 describes the
background information of the overall dissertation, mainly including brain tumor in CNS,
brain tumor segmentation, longitudinal brain tumor tracking, brain tumor growth
modeling, tumor grading, and basis of deep neural network (DNN). Chapter 3 proposes
the two methods: the feature fusion method and the joint label fusion method, for the first
dissertation goal. Chapter 4 investigates the new WHO tumor classification criteria and
also briefly introduces digital pathology image and proteomics information. State-of-theart comparison to other works is provided as well. Chapter 5 discusses the proposed
context-aware deep learning architecture for multiple tumor analysis tasks. The chapter
also briefly introduces the experimental data. Finally, the dissertation concludes in
Chapter 6, with a summary and suggestions for future work.
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CHAPTER 2
BACKGROUND REVIEW
This chapter reviews the relevant information on tumor segmentation, tumor growth
modeling, longitudinal tumor tracking, tumor grading, the artificial neural network, and
overall patient survival prediction.
2.1 Brain Tumor Segmentation
In the U.S., out of all deaths, 2.5% are caused by brain tumor. A brain tumor is a
heterogeneous mass of tissue that is formed by an accumulation of abnormal cells.
Compared to normal tissues, it has highly irregular properties, including multiple cell
phenotype, heterogeneous density, high intra-tumoral pressure, and tortuous vasculature
[28]. For diagnosis, prognosis, and treatment planning, detection and quantization of a
brain tumor is an important step. Tumors may have an unpredictable appearance, with a
huge variation in size, shape, and location, as shown in Figure 2. As such, the process of
distinguishing different abnormal tumor tissues such as necrosis (NC), peritumorally

ET

NC

ED

NE

Figure 2. Four cases of tumor on MRI. Note that these pre-processed images are overlaid
with ground truth. All data obtained from BraTS Challenge. ET-enhancing tumor, NCnecrosis, ED-peritumorally edema, NE-non-enhancing tumor.
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edema (ED), non-enhancing tumor (NE), enhancing tumor (ET), also known as brain
tumor segmentation, is very challenging.
The segmentation of the various brain tumor sub-regions (i.e., ET, NE, and ED) has
commonly been addressed as a classification problem in the existing literature [29, 30].
This involves robust feature extraction as critical for such methods, followed by SVM
and Random Forest (RF) being widely used as classifiers [13, 16, 31, 32]. The general
idea of feature-based methods is to extract features and provide them to a classifier, in
order to learn the most representative of the class(es) in question, and hence to obtain
segmentation labels in new unseen cases. In recent years, deep learning has been
successfully applied across many domains, including computer vision, speech
recognition, and medical imaging processing (brain tumor detection and segmentation),
among others. [29, 33, 34].
There are many studies proposed for image-based brain tumor segmentation in the
literature. Among conventional machine learning-based methods, K-nearest neighbors,
support vector machine (SVM), and AdaBoost are widely used [20, 21, 32]. In recent
years, deep learning-based methods have been shown to outperform conventional
machine learning-based methods for tumor segmentation. However, longitudinal brain
tumor tracking using deep learning methods may not be feasible, as these deep learning
methods need large amount of data and, in general, there is a lack of that large volume of
longitudinal tumor tracking data available.
2.2 Tumor Growth Modeling
With tumor growth modeling, we can simulate brain tumor development over time.
The interest of tumor growth simulation has many aspects. First, it provides a better

12
understanding of the physiology of the tumor growth. Second, a tumor growth model
may be used to quantify a tumor’s aggressiveness for a given patient. Finally, using the
growth model can improve therapy planning (in surgery or radiotherapy) by better
defining the tumor invasion region based on the local estimation of the tumor cell density
[24]. It can help in predicting the tumor over time from a limited number of patient
observations.
Tumor growth models can be categorized into two groups based on the observation scales
[24]:
•

Cellular and microscopic models. These models take the action behavior of
individual cell into account for the subject; more complex models consider the
interaction between the cells and the environment.

•

Macroscopic models. These models are based on local tumor cell density. Most
of the models rely upon a reaction-diffusion equation to account for tumor
propagation.

Cellular and microscopic models are widely used in the literature [35-37]; however,
these models do not consider the interactions between cells and tissues. Macroscopic
models mainly use a reaction-diffusion formalism. These models take both the
microscopic proliferation and the macroscopic diffusion into account for tumor growth.
In this study, we aim to build a tumor growth model by solving the reaction-diffusion
equation.

2.3 Longitudinal Brain Tumor Tracking
Longitudinal brain tumor segmentation prediction is not only related to the accurate
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segmentation of the various tumor sub-regions, it also reveals information about tumor
development over time. Monitoring longitudinal brain tumor changes is useful for the
follow-up of treatment-related changes, the assessment of treatment response, and the
guiding of dynamically changing treatments, including surgery, radiation therapy, and
chemotherapy. To model and predict the growth of a tumor, a reaction-diffusion equation
is generally employed [23, 24, 38-41]. Hu et al. simulated one-dimensional tumor growth
based on logistic models [42]. Sallemi et al. simulated brain tumor growth based on
cellular automata and the fast marching method [43]. Similar works for tumor growth
prediction are proposed in [23, 24, 28, 39, 41, 44]. However, none of these methods
explicitly obtains tumor segmentation using growth patterns as features. Clatz et al.
proposed a GBM tumor growth simulation by solving a reaction-diffusion equation using
the finite element method [45]. Xu et al. used phase fields to model cellular growth and
reaction-diffusion equations for the dynamics of angiogenic factors and nutrients [46].
We recently proposed a novel tumor cell density feature obtained from a tumor growth
model which assesses temporal changes of tumor cell density based on biophysical tumor
growth modeling, for segmentation prediction [14].
Tumor growth modeling, combined with segmentation, is useful in understanding the
extent of a tumor as the tumor growth. Bauer et al. proposed tumor growth-based
segmentation [47]. Boosted Glioma Image Segmentation and Registration
(GLISTRboost), a state-of-the-art method, is used for segmentation by incorporating a
glioma growth model [48]. GLISTRboot utilizes a gradient boosting multi-class
classification. Brain Tumor Image Analysis (BraTumIA) is a tool for longitudinal brain
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tumor segmentation [49]; however, both state-of-the-art tools ignore the internal
relationship between different timepoint scans.
As noted above, current works that discuss longitudinal brain tumor tracking in the
literature highly focus on tumor segmentation, mostly ignoring the importance of tumor
growth. Another challenge to the work is the lack of longitudinal tracking data. In this
study, we propose novel methods for longitudinal tumor tracking by integrating tumor
segmentation and tumor growth modeling with a limited amount of longitudinal MRI
data.
2.4 Brain Tumor Grading
Based on the similarity of tumor cells to normal cells, the growth rate, the presence of
definitive tumor margins, and the vascularity, they are classified as Grade I, II, III, and IV
by the World Health Organization (WHO) [3]. Grade I tumors are the most discrete, with
a slow growth rate. Grade II tumors have a slow growth rate, but are able to invade
surrounding tissue. Grade III tumors have actively reproducing abnormal cells that
infiltrate adjacent cells, and Grade IV tumors are the most malignant, with rapid
proliferation and infiltration to surrounding tissue [50-52]. Grades III and IV are
categorized as high grade, and the rest are low grade.
A new CNS brain tumor grade classification standard was released by the WHO in
2016 [4]. Due to the drawbacks of tumor grading based only on histology, proteomics
information has recently been used for tumor classification [53-56]. With the new
standard for tumor grading, isocitrate dehydrogenase (IDH) mutation in proteomics
information is identified as one of the major criteria [57]. In addition, other molecular
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mutations, such as ATRX, X1p/19q codeletion, and MGMT have also been studied for
glioma proteomics classification [58].

2.5 Artificial Neural Networks
Artificial neural networks (ANNs) are computing methods inspired by the biological
neural networks of human/animal brains. An ANN is composed of neurons, which are
simple and interconnected processors. The neurons are interconnected for signal
processing. The process consists of data collection, analysis and processing, network
structure design, the number of hidden layers, the number of hidden units, initializing,
training the network, network simulation, weights/bias adjustments, and testing the
network [59]. ANNs are considered as a universal approximators that have the ability to
approximate a given function distribution. A neuron is the main component of a neural
network, and the perceptron is the most used model. Figure 3 shows a graphical
representation of a perceptron.

Figure 3. A graphical representation of a perceptron. 𝑥𝑖 and 𝜔𝑖 are inputs to the
neuron and the corresponding weight, respectively. 𝑓(∙) is an active function. 𝑦 is the
final output.
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Label 𝑥0 , 𝑥1 … , 𝑥𝑛 are the inputs to the neuron. Note that the input 𝑥0 in the model is
a fixed input that is typically set to 1 and provides a weighted external bias to the neuron.
Each input to the neuron is multiplied with the corresponding weights, and then summed
together. The final output is obtained by transforming the summation via an activation
function, 𝑓(∙). The model can be mathematically written as follows:
𝑦 = 𝑓(𝑠) = 𝑓(∑𝑛𝑖=0 𝑥𝑖 ∙ 𝜔𝑖 )

(1)

The popular activation functions include sigmoid, tanh function, sin/cos function,
polynomial function, rectified linear, etc.

2.5.1 Multilayer Perceptron
A multilayer perceptron (MLP) is a class of feedforward ANN that contains one or
more hidden layers and can learn non-linear functions. A typical MLP with a single
hidden layer is shown in Figure 4. The leftmost layer is called the input layer. The
rightmost layer is the output layer. The middle layer is called the hidden layer [60]. The
Input layer

Hidden layer

𝑥1

ℎ1

𝑥2

ℎ2

𝑥𝑛

Output layer

𝑦

ℎ𝑚

Figure 4. A graphical representation of a multilayer perceptron with a
single hidden layer.

𝑦
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MLP shows the capability to approximate any sufficiently smooth function, and it is
regarded as a universal approximator.
In a supervised MLP model, the ultimate goal is to minimize the error or the cost
function between the target and the prediction obtained from the model. To adjust the
training weights and biases using a gradient descent algorithm, the backpropagation
algorithm is well-known for computing such gradients [61]. MLP is a popular machine
learning solution, and it has been successfully used in diverse fields, such as speech
recognition, image recognition, and others.
2.5.2 Convolutional Neural Network
Convolutional neural network (CNN) is a class of deep neural networks most
commonly used for visual imagery analysis. The idea of CNN is not new, but its
application has been limited due to memory and hardware constraints [62]. Since the
mid-2000s, deep neural network training has been feasible because of the increased
availability of large datasets and hardware improvements. Figure 5 shows MNIST [63]
handwritten digits recognition, using CNN.
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Pooling layer
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Convolutional
layer

Connection
Connection layer
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Figure 5. A CNN application for handwritten digits recognition.

Output
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A typical CNN contains convolutional layer, a pooling layer, an activation function,
and a fully connected layer. The convolutional layer determines the output of the neurons
that are connected to the local regions of the input through convolutional operation. The
pooling layer performs downsampling along the spatial dimensionality of the given input,
and further reduces the number of parameters within that activation [64]. Max pooling is
the most commonly used for reducing the spatial size of feature maps. The activation
function usually follows the convolutional layer. Nonlinearity between layers ensures that
the model is more expressive than a linear model [62]. The activation functions include
sigmoid, tanh, rectified linear unit (ReLU), and leaky-ReLU, among others. The fully
connected layer contains neurons that are directly connected to the neurons in the two
adjacent layers, without being connected to any layers within them [64]. It usually
produces class scores from the activations in a classification application.

2.6 CNN-based brain tumor segmentation
In recent years, CNN-based methods have been successfully applied in medical
imaging analysis, such as in brain tumor segmentation [33, 34], nuclei segmentation [65],
and liver segmentation [66]. There are different methods for preparing input data for
CNN-based tumor segmentation methods, such as patch-based [34], 2D slice-based [67],
and 3D volume-based [33]. Each method has advantages and disadvantages. The patchbased method has the fastest training process, yet it may produce lots of misclassification
in testing phase. The 2D slice-based method has a moderate training time and generates a
more accurate result than that of patch-based method in the testing phase. The 3D
volume-based method requires large graphic processing unit (GPU) memory. The 3D
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volume-based method takes the longest training time, but provides the best performance
in the testing phase, compared to the other two methods. All of the CNN architectures
used for brain tumor segmentation have both encoding and decoding modules. The
encoding module is used to extract the convolutional dense features, and the decoding
module is used to reconstruct the dense features to the corresponding segmentation. The
trainable network attempts to minimize the loss between segmentation and ground truth.
The CNN-based method offers the best state-of-the-art performance in tumor
segmentation. Comparing the patch-based to the 3D volume-based method, the
improvement for the 3D method mainly depends on the computational capability of the
GPU. Most brain tumor cases have much more peritumorally edema than necrosis; this
causes a data imbalance problem that may not help much for the 3D volume-based
method in distinguishing the majority and the minority sub-tumors. We, however,
propose a context-aware deep learning-based method that captures a global context
information for relieving the data imbalance issue and helps to achieve better tumor
segmentation performance.
2.7 Patient Survival Prediction
In general, patients with LGG have a longer survival period than those with HGG.
Patient survival prediction is important for prognosis. Recently, the focus has been
shifted to predicting the clinical outcome with non-invasive methods, instead of using
invasive methods [68, 69]. There are many studies about predicting the survivability of
patients with brain tumors in the literature [70, 71]. All of these methods extract a large
number of radiomic image features, including shape and texture, in computed
tomography images of the patient with brain tumors, and then apply regression methods
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for survival prediction. Zeina et al. propose a feature-guide deep radiomics for
glioblastoma patient survival prediction [69]. The authors first use a hybrid method for
tumor segmentation, which utilizes RF and UNet, and then they extract volumetric
features and texture features, including piecewise triangular prism surface area (PTPSA)
and multi-fractional Brownian motion (mBm). Finally, XGBoost is applied on these
features for the survival prediction.
Since hand-crafted feature extraction is very challenging, CNN may be used as a
dense feature extraction tool. Few CNN-based methods are also proposed for survival
prediction [72, 73]. However, many of these methods study survival prediction and
segmentation independently, without exploring the inter-connection between survival
prediction and tumor segmentation steps. In this work, we propose a feature-based
method for survival prediction by integrating a tumor segmentation step using a CNN.
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CHAPTER 3
IMPROVED LONGITUDINAL BRAIN TUMOR TRACKING

3.1 Chapter Overview
This chapter proposes a novel longitudinal brain tumor segmentation prediction using
two different fusion approaches. The first one is called as “feature-fusion” approach,
where unique tumor growth-based cell density and texture features are used. The second
approach refers to label-fusion, where segmentation labels obtained from two state-ofthe-art tumor growth and stochastic texture models are utilized. In the feature-fusionbased segmentation prediction method, we build upon a stochastic multiresolution texture
model to obtain cell density information from tumor growth patterns as novel features
and then fuse them with texture features. The tumor growth model is based on a reactiondiffusion equation that is solved in 3D using a Lattice-Boltzmann method (LBM), a class
of computational fluid dynamics method for fluid simulation. On the other hand, the
proposed joint label-fusion method fuses segmentation labels obtained from a hybrid
generative-discriminative brain tumor segmentation method that incorporates a
biophysical tumor growth model and the stochastic tumor segmentation models, to
achieve tumor segmentation predictions. For traditional multi-atlas label fusion, multiple
target images are registered and weighted by comparing target image to multiple atlas
images. Further, the reference labels are obtained by considering tissue labels from
registering the target image to the atlas images. In this study, due to the presence of
multiple tumors in the provided mMRI volumes, we did not use healthy atlases as
reference images, but instead created consensus average images across all patients for
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each MRI modality. The reference labels are obtained by the RF and the GB
segmentation models. The fusion weight is obtained proportional to inverse of intensity
difference by target images to reference images.

3.2 Literature Review
This section provides a brief literature review on brain tumor segmentation, tumor
segmentation prediction.
3.2.1 Brain Tumor Segmentation
Brain tumors may be classified as benign or malignant based on grade, and primary
or metastatic based on origin. According to the World Health Organization (WHO),
tumors of the central nervous system (CNS) may be graded as I, II, III and IV, based on
multiple factors including similarity of tumor cells to normal cells, growth rate, presence
of definitive tumor margins, and vascularity. Among these classes, grade III tumors
contain actively reproducing abnormal cells that infiltrate between adjacent cells, and
grade IV tumors are the most malignant with rapid tumor cell proliferation and
infiltration to surrounding tissues [51, 52]. Recently, WHO suggested a new CNS tumor
classification, based on both phenotype and genotype expressions in addition to growth
pattern and behaviors [4]. Glioblastoma (formerly glioblastoma multiforme, GBM) is the
most common and deadly among all human primary CNS tumors [5], with extensive
heterogeneity radiographically reflected by various sub-regions, comprising enhancing
(ET) and non-enhancing tumor (NET), as well as peritumorally edematous/invaded tissue
(ED). Glioblastoma originates from glial cells and grows by infiltrating surrounding
tissues. Even though there have been many treatment advancements, the median overall
survival period of patients diagnosed with GBM still remains 12-16 months [5].
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The segmentation of the various brain tumor sub-regions (i.e., ET, NET, and ED) has
commonly been addressed as a classification problem in existing literature [29, 30], with
robust feature extraction being critical for such methods, and SVM and convolutional
neural networks (CNN) being widely used as classifiers. The general idea of featurebased methods is to extract features and provide them to a classifier, to learn the most
representative of the class(es) in question, and hence obtain segmentation labels in new
unseen cases. However, to the best of our knowledge, tumor cell density pattern has not
been used as a feature in tumor segmentation prediction by others. The cell density
feature can be obtained from solving the biophysical tumor growth modeling such that to
predict potential tumor development in the future.
Brain tumor detection, segmentation, and tracking its changes over time (henceforth,
tumor segmentation prediction) is of particular importance for diagnosis, treatment
planning, and monitoring. In practice, manual tumor segmentation by radiologists is
tedious, time consuming and prone to human error. Brain tumor segmentation over time
is a critically challenging task due to its unpredictable appearance, infiltration to
surrounding tissue, intensity heterogeneity, size, shape, and location variation [18]. There
are many brain tumor segmentation techniques published in the literature. Gooya et al.
introduced a generative approach for registering a probabilistic atlas of a healthy
population to brain MRI scans with glioma and simultaneously segmenting these scans
into tumor and healthy tissue labels [40, 74]. Cuadra et al. proposed an atlas-based
segmentation of pathological brain MRI scans using a lesion growth model [75]. Bauer et
al. also introduced an atlas-based segmentation of brain tumor images using a Markov
random field-based tumor growth model and non-rigid registration [47]. However, these

24
atlas-registration based techniques may be tedious and error prone since they require
accurate deformable image registration of tumor bearing slices with the atlas. To avoid
the issues with image registration, other studies consider the brain tumor segmentation as
a feature-based classification problem. Islam et al. extracted sophisticated texture features
among others and applied the AdaBoost algorithm to segment tumors [76]. Reza et al.
proposed an improved texture features based multiple abnormal brain tissue classification
method using Random Forest (RF) [17, 77]. Support vector machine (SVM) has also
been used as a classifier for brain tumor segmentation [21]. In addition, others have
utilized super-pixels to classify tumor tissue. Wang et al. used a graph-based
segmentation technique to over-segment images into homogeneous regions [78, 79]. Pei
et al. applied simple linear iterative clustering (SLIC) to obtain super-pixel [22].
Kadkhodaei et al. applied a semi-supervised “tumor-cut” method to over-segment
images. The super-pixel-based segmentation relies on the quality of the approach used for
the over-segmentation. Finally, over recent years, various approaches based on CNN
have been used for brain tumor segmentation [29, 80].

3.2.2 Longitudinal Brain Tumor Tracking
Longitudinal brain tumor segmentation prediction is not only related to the accurate
segmentation of the various tumor sub-regions, but also reveals information about the
tumor development over time. Monitoring longitudinal brain tumor changes is useful for
follow-up of treatment-related changes, assessment of treatment response and guiding
dynamically changing treatments, including surgery, radiation therapy, and
chemotherapy. Figure 6 shows a longitudinal brain tumor example for a patient from
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BraTS 2015 patient dataset [18]. This figure shows that enhancing, necrosis and other
surrounding tissues of the tumor for an example patient in timepoint 2 are evolving
(increasing) during the elapsed time by comparing that of timepoint 1.

Figure 6. A longitudinal brain tumor example. Top row from left to right: T1, T1c,
T2, T2-FLAIR, and ground truth (GT) at timepoint 1. Bottom row shows the
corresponding images at timepoint 2 (282 days after timepoint 1).
To model and predict the growth of a tumor, a reaction-diffusion equation is generally
employed [23, 24, 38-41]. Hu et al. simulated one-dimensional tumor growth based on
logistic models [42]. Sallemi et al. simulated brain tumor growth based on cellular
automata and fast marching method. However, none of these methods explicitly obtains
tumor segmentation using growth patterns as features. Clatz et al. proposed a GBM
tumor growth simulation by solving the reaction-diffusion equation using finite element
method [45]. Xu et al. used phase fields to model cellular growth, and reaction-diffusion
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equations for the dynamics of angiogenic factors and nutrients [46]. We recently
proposed a novel feature, which assesses temporal changes of tumor cell density, based
on biophysical tumor growth modeling, for segmentation prediction [21]. Meier et al.
used a fully automatic segmentation method for longitudinal brain tumor volumetry [49].
However, Meier’s work only focuses on analyzing each timepoint independently, and
does not include a setting to integrate knowledge from prior timepoints for longitudinal
tumor study.

3.3 Background
In this section, we discuss texture features, random forest (RF) classification, tumor
growth modeling, and joint label fusion.
3.3.1 Multi-fractal Brownian Motion (mBm) Texture Feature Extraction
The mBm is a nonstationary zero-mean Gaussian random process that corresponds to
the generalization of fractional Brownian motion (fBm) [17]. The fBm considers a rough
heterogeneous appearance of tumor texture in brain MRI. In the fBm process, the local
degree of Hurst index (H) is a constant. The value of 𝐻 determines the randomness of the
fBm process. However, tumor texture in MRI may appear as a multifractal structure that
is a time (t) and/or space varying process and is represented by mBm. The mBm process
is defined as 𝑥(𝑎𝑡) = 𝑎𝐻(𝑡) 𝐻(𝑡), where 𝑥(𝑡) is the mBm process with a scaling factor, 𝑎,
and the time varying Hurst index 𝐻(𝑡). The mBm features effectively model spatially
varying heterogeneous tumor texture. Its derivation combines the multi-resolution
analysis enabling one to capture spatially varying random inhomogeneous tumor texture
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at different scales [76]. More details for these multiscale texture features and their
efficacy in brain tumor segmentation can be found in [17, 76, 77].
3.3.2 Random Forest Classification
Random forest (RF) is an ensemble learning method for classification, regression, and
other tasks [81]. The RF classifier is heavily used for medical image analysis due to its
very fast, and efficient multi-class handling capability. Assume there are 𝑛 samples and
𝑛
(𝑣⃑𝑖 )𝑐𝑣⃑𝑖=1
feature vectors with outcomes 𝑦𝑖 . Data is represented as: 𝐷 =

[(𝑣⃑1 , 𝑦1 ), ⋯ , (𝑣⃑𝑛 , 𝑦𝑛 )]. The feature vector (𝑑 dimension) of a sample 𝑣⃑𝑖 is represented by
𝑣⃑𝑖 = (𝑣𝑖1 , ⋯ , 𝑣𝑖𝑑 ). A classification tree is a decision tree, in which each node has a
binary decision based on whether 𝑣⃑𝑖 is less than a threshold 𝛼. At each node, feature 𝑣𝑖𝑑
and threshold 𝛼 are chosen to minimize resulting ‘diversity’ in the children nodes that are
measured by Gini criterion. Ensemble of classifiers ℎ = [ℎ1 (𝑣⃑), ⋯ , ℎ𝐾 (𝑣⃑)] and we define
parameters of the decision tree for each classifier ℎ𝑘 (𝑥) to be 𝜃𝑘 = (𝜃𝑘1 , 𝜃𝑘2 , ⋯ , 𝜃𝑘𝑝 ).
We can write: ℎ𝑘 (𝑣⃑) = ℎ(𝑣⃑|𝜃𝑘 ). A RF classification is based on a family of classifiers
[{ℎ(𝑣⃑|𝜃𝑘 ), 𝑘 = 1, ⋯ , 𝐾}] with parameters 𝜃𝑘 , which are randomly chosen from a model
vector 𝜃.
In RF classification, given a fixed ensemble ℎ = [ℎ1 (𝑣⃑), ⋯ , ℎ𝐾 (𝑣⃑)], where 𝑣⃑ is a
random vector and 𝐾 is the number of trees in the forest, the estimated probability for
predicting class 𝒸 for a sample set, is defined as:
1

𝑝(𝒸|𝑣⃑) = 𝐾 ∑𝐾
⃑),
𝑡=1 𝑝𝑡 (𝒸|𝑣

(2)

where pt (𝒸|𝑣⃑) is the estimated density of class labels at the 𝑡𝑡ℎ tree. The final multi-class
decision function of the forest is defined as:
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𝐶(𝑣⃑) = 𝑎𝑟𝑔 𝑚𝑎𝑥 𝑝(𝒸|𝑣⃑),
𝒸𝜖𝑙

(3)

There generalization error (𝐺𝐸) has an upper bound in form of
𝐺𝐸 ≤ 𝜌̅

1−𝑠2
𝑠2

,

(4)

where 𝜌̅ is the mean correlation between pairs of trees in the forest, and 𝑠 is the strength
of the set of classifiers.
3.3.3 Biophysical Tumor Growth Model
Tumor growth describes an abnormal growth of tissue, which usually involves cell
proliferation, invasion, and mass effect to the tumor surrounding tissues. During cell
invasion, tumor cells migrate as a cohesive and multicellular group with retained cell-cell
junctions and penetrate to surrounding healthy tissues. Tissues in the brain may deform
due to mass effect. Biophysical tumor growth modeling simulates the interactive process
occurring between the abnormal tissue (i.e., tumor) and the surrounding brain tissues, and
parameterizes the collective changes in the brain, including death, infiltration to
surrounding tissues, and proliferation. The reaction-diffusion equation has been widely
used to model brain tumor growth [23, 39, 41, 42], using a diffusion and a logistic
proliferation term given as:
𝜕𝑛𝑠
𝜕𝑡

= 𝐷𝛻 2 𝑛𝑠 + 𝜌𝑛𝑠 (1 − 𝑛𝑠 ),
𝐷𝛻𝑛𝑠 . 𝑛⃗𝜕Ω = 0,

(5)
(6)

where 𝑛𝑠 is the tumor cell density, 𝐷 is the diffusion coefficient while infiltrating, and 𝜌
is the proliferation rate. Equation (5) enforces Neumann boundary conditions on the brain
domain Ω, and 𝑛⃗ is unit normal vector on the 𝜕Ω pointing inward to the domain.
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3.3.4 Joint Label Fusion
Joint label fusion has been developed in recent years and used for analysis of medical
images [22, 78]. Comparing to the single-atlas based method, multi-atlas-based label
fusion reduces errors associated with any single atlas propagation in the process of
combination, and the weight for each atlas is computed independently. However,
different atlases may produce similar label errors. To solve this issue, Wang et al.
proposed an advanced multi-atlas label fusion, known as joint label fusion [82]. Multiatlas label fusion enforces co-registration with sample images to target image and
minimizes independent errors to improve the segmentation result [83]. In general, the
label map 𝐿̂ is computed by using the following equation:
𝐿̂ = 𝑎𝑟𝑔 𝑚𝑎𝑥 𝑝(𝐿|𝐼; 𝐼̂𝑛 , ∅𝑛 ),
𝐿

(7)

where 𝐼̂𝑛 is the n-th training image, and ∅𝑛 is the transfer function during image
registration. 𝐿 is the candidate label map of the testing image 𝐼. Joint label fusion
achieves consensus segmentation given as,
𝐿̅ = ∑𝑛𝑖=1 𝜔𝑖 (𝑥)𝑝(𝑙|𝑥, 𝐼̂𝑛 ),

(8)

where 𝜔𝑖 (𝑥) is individual voting weight, and 𝑝(𝑙|𝑥, 𝐼̂𝑛 ) is the probability that 𝑥 votes for
label 𝑙. The weight is determined by:
𝑀−1 1

𝜔𝑥 = 1𝑡 𝑀𝑥 −1𝑛1 ,
𝑛

𝑥

𝑛

(9)

where 1𝑛 = [1; 1; ⋯ ; 1] is a vector of size 𝑛 and 𝑀𝑥 is the pairwise dependency matrix
that estimates the likelihood of two atlases both producing wrong segmentations on a pervoxel basis for the target images.
The dependency matrix is computed as:

30
𝐿

𝑚
𝑚
𝑚
𝑀
〈|𝐴𝑚
𝑀𝑥 (𝑗, 𝑘)~ ∑𝑚=1
𝐹 (Ʊ(𝑥(𝑗))) − 𝑇𝐹 (Ʊ(𝑥))| , |𝐴𝐹 (Ʊ(𝑥(𝑘))) − 𝑇𝐹 (Ʊ(𝑥))|〉,

(10)

𝑚
where 𝑚 indices correspond to all modality channels, and |𝐴𝑚
𝐹 (Ʊ(𝑥(𝑗))) − 𝑇𝐹 (Ʊ(𝑥))|

is the vector of absolute intensity difference between a selected atlas image and the target
image over local patches Ʊ centered at voxel 𝑥(𝑗) and 𝑥, respectively. 〈∙,∙〉 is the dot
product. 𝐿𝑀 is the total number of modalities [82].
3.4 Methods
This study proposes two distinct methods for longitudinal brain tumor segmentation
prediction: a feature-based and joint-label fusion-based. Application of the proposed
methods, assumes appropriate pre-processing of the provided multimodal MRI brain scans,
consisting of noise reduction, bias field correction, scale standardization, and histogram
matching.
3.4.1 Feature Fusion Based Method
The method proposed in this study utilizes tumor growth patterns as novel features to
improve texture-based tumor segmentation in longitudinal MRI. The proposed pipeline is
shown in Figure 7.
By using the proposed feature-based fusion, the vector 𝑣 is defined as:
𝑣

= [𝐹𝐷, 𝑛𝑠 , 𝐼𝑝𝑟𝑒 , 𝐼𝑝𝑜𝑠𝑡 , ⋯ , 𝐻𝑖𝑠𝑡],

(11)

And the label of target image is defined as:
1

𝐿 = 𝑎𝑟𝑔𝑚𝑎𝑥 𝐾 ∑𝐾
⃑ ),
𝑡=1 𝑝𝑡 (𝒸|𝜃𝑘 , 𝑣
𝑐𝜖𝐿

(12)

where 𝒸 is the candidate label of the target image. 𝐾 is number of trees applied. 𝑣⃑ is a
feature vector. θk is the classifier parameter obtained from training process at 𝑘 𝑡ℎ tree.
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𝐹𝐷 describes the mBm features, 𝑛𝑠 is the tumor cell density as derived by the tumor
growth model (Eq. 5), 𝐼𝑝𝑟𝑒 and 𝐼𝑝𝑜𝑠𝑡 are the image intensities before and after intensity
normalization (scale standardization [84]), respectively. 𝐻𝑖𝑠𝑡 is the intensity histogram of
all modalities (T1, T1c, T2, and T2-FLAIR).

Figure 7. Pipeline of the proposed method. At the 1st scan date, we extract texture

(e.g., fractal, and mBm) and intensity features, and obtain the ground truth label
map for different brain tissues from baseline pre-operative (i.e., first timepoint)
multimodal MRI scans. The ground truth at this first timepoint is used to obtain the
tumor growth modeling and enable to predict cell density for the next timepoint.
Finally, considering the cell density pattern as a new feature, we fuse it with other
features using a RF classifier to generate the label of second timepoint.
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Two feature types were used in the proposed method, representing local and spatial
descriptors. Local features comprise the intensity of each modality before and after
scaling standardization, as well as after histogram matching, their pairwise intensity
differences among image modalities, and the cerebrospinal fluid (CSF) mask, obtained by
the CSF expected intensity across modalities. Spatial features include a fractal feature
extracted from multi-modal MRI, named piecewise-Triangular Prism Surface Area
(PTPSA), the mBm features that combine both multiresolution-fractal and wavelet
analyses for each modality after scaling standardization, and 6 gabor-like Texton
features.
3.4.2 Joint Label Fusion Based Method
Label fusion has been successfully used for tumor segmentation in recent years [82,
83]. The method proposed here employs joint label fusion for improving tumor
segmentation prediction by fusing stochastic feature-based tumor labels, with

Figure 8. Pipeline for joint label fusion-based tumor segmentation prediction.
segmentation labels obtained from a hybrid generative-discriminative brain tumor
segmentation method that incorporates a biophysical tumor growth model, namely
GLISTRboost [48, 85, 86] (GB). The proposed pipeline is shown in Figure 8. Initially,
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GB is applied on the 2nd timepoint in parallel with independent application of the RFbased approach, and their output segmentation labels are then fused together leading to
the consensus result.
All provided MRI scans were affinely co-registered to an atlas template [87] and
skull-stripped by BraTS. We then scaled all modality intensities for one reference subject
to the range [0-255] and then matched the histograms of each modality across all
subjects. The error dependence matrix (Eq. 10) was then computed between the target
and the reference image, which describes the consensus average images across all
patients. By using the error dependency matrix, we calculate the voting weight (Eq. 9),
and finally the agreement label (Eq. 8) is obtained.
In GB, the probabilities of ET and NE are defined as:
𝑓(𝑌|𝛷, ℎ, 𝑞) = ∏𝑥∈𝛺 ∑𝐾
𝑘=1 𝜋𝑘 (ℎ(𝑥)|𝑞)𝑓𝑘 (𝑦(𝑥)|𝛷),

(13)

where 𝑌 is the observation set, 𝛷 is the intensity distribution, ℎ the reference domain, 𝑞
the tumor growth model parameters, 𝜋𝑘 the 𝑘 abnormal tissue, and 𝑓𝑘 (∙) is a multivariate
Gaussian distribution.
Application of the joint label fusion method requires all four provided MRI volumes,
the label map 𝐿𝐺𝐵 obtained by GB (Eq. 14), and the segmentation result 𝐿𝑅𝐹 obtained by
Eq. 3 and 4. The voting weights are obtained by computing the error dependency matrix
from all the available modalities to the reference images (Eq. 10). For calculating the
dependency matrix (Eq. 10), Ʊ(𝑥) is a 5 × 5 × 5 patch centered at location 𝑥. 𝐴𝑚 (𝑚 ∈
[1, 2, 3, 4] describes the volumes T1, T1c, T2, and T2-FLAIR of the training images,
respectively. 𝑇 𝑚 is the target image. A is the reference image including the GB
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segmentation (AGB ) and RF classification (ARF ). The candidate labels at location 𝑥 for
either the GB or the RF segmentations are defined as:
𝑝(𝑙|𝑥) = ∑2𝑖=1 𝜔𝑥(𝑖) 𝑝(𝑙|𝑥(𝑖), 𝐴(𝑖)) = 𝜔𝑥(1) 𝑝(𝑙|𝑥(1), 𝐴𝐺𝐵 ) + 𝜔𝑥(2) 𝑝(𝑙|𝑥(2), 𝐴𝑅𝐹 ) =
−1
𝑀𝑥(1)
1𝑁
−1 1
1𝑡𝑁 𝑀𝑥(1)
𝑁

−1
𝑀𝑥(2)
1𝑁

𝑝(𝑙|𝑥(1), 𝐴𝐺𝐵 ) + 1𝑡

−1
𝑁 𝑀𝑥(2) 1𝑁

𝑝(𝑙|𝑥(2), 𝐴𝑅𝐹 ) ,

(14)

Let’s define Dirac delta function 𝛿(𝑙|𝑥) as 1, if the predicted label is the same as the
reference label, otherwise 0, then, Eq. (13) becomes:
−1
𝑀𝑥(1)
1𝑁

𝑝(𝑙|𝑥) = 1𝑡

−1
𝑁 𝑀𝑥(1) 1𝑁

−1
𝑀𝑥(2)
1𝑁

𝛿𝐺𝐵 (𝑙|𝑥) + 1𝑡

−1
𝑁 𝑀𝑥(2) 1𝑁

𝛿𝑅𝐹 (𝑙|𝑥) ,

(15)

where the dependency matrix of 𝑀 is computed by using Eq. 10. In the special case of
−1
𝑀𝑥(1)
1𝑁

the images among atlases being the same, 1𝑡

−1
𝑁 𝑀𝑥(1) 1𝑁

−1
𝑀𝑥(2)
1𝑁

= 1𝑡

−1
𝑁 𝑀𝑥(2) 1𝑁

= 0.5, then the Eq. 15

will be simplified as a majority voting method, and 𝑝(𝑙|𝑥) = 0.5(𝛿𝐺𝐵 (𝑙|𝑥) + 𝛿𝑅𝐹 (𝑙|𝑥)).
Therefore, it is recommended to choose an odd number of templates.
3.4.3 Lattice-Boltzmann Method for Tumor Growth Modeling
To solve the reaction-diffusion equation (Eq. 5), different methods such as finite
element method (FEM) [24] and Lattice-Boltzmann method (LBM) [41] may be used.
We use the LBM method, due to its computational efficiency and easy parallelization.
The LBM is defined as [88]:
𝑓𝑠 (𝑥 + 𝑒𝑖 , 𝑖 , 𝑡 + 1) − 𝑓𝑠 (𝑥 , 𝑖 , 𝑡) = 𝛺𝑆𝑁𝑅 + 𝛺𝑆𝑅 ,

(16)

where 𝑓𝑠 (𝑥, 𝑖 , 𝑡) is the one particle distribution function of specifies 𝑠 with velocity 𝑒𝑖 at
R
time 𝑡 and dimensionless position 𝑥. ΩNR
S is non-reactive term. 𝛺S is active term.

𝛺𝑆𝑁𝑅 = −

𝑒𝑞
[𝑓𝑠 (𝑥,𝑖 ,𝑡)−𝑓𝑠 (𝑥,𝑖 ,𝑡)]

𝜏

,

(17)
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𝑒𝑞
where 𝜏 is the relaxation time. 𝑓𝑠 (𝑥, 𝑖 , 𝑡) is the equilibrium distribution function, which

depends on 𝑥 and 𝑡 corresponding to a system with zero mean flow given as:
𝑒𝑞

𝑓𝑠

= 𝜔𝑠,𝑖 𝑛𝑠

(18)

Two-dimensional nine-velocity (D2Q9) model is commonly used in 2D cases. The
nine discrete velocities are shown in Figure 9.

Figure 9. Illustration of the nine discrete velocities in a D2Q9 model.
Let’s define:
𝑒𝑞
𝑛𝑠 (𝑥 , 𝑡) = ∑𝑖 𝑓𝑠 (𝑥 , 𝑖 , 𝑡) = ∑𝑖 𝑓𝑠 (𝑥 , 𝑖 , 𝑡),

(19)

Here, 𝑛𝑠 is the cell density (Eq. 5), and 𝑤𝑠,𝑖 is dependent on the lattice system:
4

𝜔𝑠,𝑖 =

9
1
9
1

,

𝑖=9

, 𝑖 = 1, 3, 5, 7
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(20)

, 𝑖 = 2, 4, 6, 8

By using LBM, the reaction-diffusion equation (Eq. 5) can be recovered as:
𝜕𝑛𝑠
𝜕𝑡

1

1 𝜕 2 𝑛𝑠

3

2

= (𝜏𝑠 − )

𝜕𝑥 2

+ 𝜌𝑛𝑠 (1 − 𝑛𝑠 ),

𝛺𝑆𝑅 = 𝜌𝑛𝑠 (1 − 𝑛𝑠 ),

(21)

(22)
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Setting 𝐷 =

1
3

1

(𝜏𝑠 − 2) offers solution for Eq. 5.

The algorithm of the proposed method is listed in Figure 10.
Algorithm
/* Initialization*/
Initialize the diffusion coefficient D & proliferation rate 𝜌 for a specific tissue.
Initialize weights (Eq. 20).
Set boundary for LBM working space.
Initialize 𝑛𝑠 as a matrix with tumor density at starting position.
Repeat until set time limit is reached.
/*Assignment*/
For 𝑖 = 1: 9
Streaming step: move 𝑓𝑠 → f𝑠∗ in direction of e⃗i .
If the cell hits the boundary
Tumor cell moves in opposite direction with same speed.
Else
Compute 𝑓𝑠𝑒𝑞 (Eq. 18).
Collision step: calculate the updated distribution function 𝑓𝑠 (Eq. 16).
End
End
Compute cell density 𝑛𝑠 (Eq. 19).
Figure 10. Algorithm for solving the biophysical tumor growth model using LBM.
3.4.4 Longitudinal Tumor Segmentation Prediction
By longitudinal tumor segmentation prediction, we refer to the accurate delineation of
the tumor boundaries in any follow up timepoint, given the segmentation of the tumor in
the first scan. This does not only allow for the segmentation of the tumor but it also
reveals information about its longitudinal growth and aggressiveness/behavior.
For feature fusion-based method, we build a tumor growth model by solving the
reaction-diffusion equation using LBM. Diffusion coefficient 𝐷 and proliferation rate 𝜌
are important parameters to simulate tumor growth using the model. To predict tissues
growth using the model, the parameters of the model are suggested within
[0.02, 1.5]𝑚𝑚2 /𝑑𝑎𝑦, and [0.002, 0.2]/𝑑𝑎𝑦 [41]. We empirically set 𝐷𝑁𝐶 , 𝜌𝑁𝐶 as 0.052,
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0.01, 𝐷𝐸𝐷 , 𝜌𝐸𝐷 as 0.06, 0.009, 𝐷𝑁𝐸 , 𝜌𝑁𝐸 as 0.03, 0.014, 𝐷𝐸𝑇 , 𝜌𝐸𝑇 as 0.05, 0.01 for NC,
ED, NE, and ET, respectively. For the JLF method, we integrate a stochastic texture
feature-based segmentation with another state-of-the-art, named GLISTRboost (GB) to
achieve a better segmentation.

3.5 Experiment
3.5.1 Data
The brain tumor scans used to quantitatively evaluate the proposed methods in this
study belong to retrospective longitudinal multi-institutional cohorts of patients
diagnosed with glioblastoma, from the publicly available Multimodal BRAin Tumor
Segmentation (BraTS 2015) challenge dataset [18]. Nine patients with longitudinal
multimodal MRI (mMRI) scans with growing tumors along time were chosen from the
BraTS 2015 dataset. The brain scans for each patient consist of four MRI modalities,
namely native T1-weighted (T1), contrast-enhanced T1-weighted (T1c), T2-weighted
(T2) and T2 Fluid-attenuated inversion recovery (T2-FLAIR).
Note that we use the BraTS 2015 dataset instead of the latest BraTS 2018 dataset [18,
86], as the latter provides only pre-operative mMRI scans, whereas the BraTS 2015 data
describes paired combinations of pre- and post-surgical mMRI brain scans for each
patient, with isotropic resolution images of size 240*240*155. The manually evaluated
ground truth labels of these brain scans were also available, allowing for the quantitative
validation of the proposed methods. These ground truth labels delineate the tumor subregions of necrotic/fluid-filled core (NC), non-enhancing/solid tumor (NE), ET, ED, and
everything else grouped together, with labels of 1, 3, 4, 2, and 0, respectively.
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3.5.2 Performance Evaluation
In the BraTS dataset, the ground truth is manually annotated by qualified raters,
following a hierarchical majority voting rule [18]. To quantitatively evaluate the proposed
brain tumor segmentation prediction method, a criteria policy is required. Specifically,
there are three different tumor regions, as defined by the BraTS challenge [18]:
1) Region 1 – Whole tumor (WT)
This region defines the whole tumor (WT). Consistent with the BraTS challenge [18],
the WT consists of the union of all tumor labels. Although the ED is a peripheral tissue to
the tumor core, it is still considered as part of the WT since it is not pure edema but also
includes invaded tumor cells.
2) Region 2 – Tumor core (TC)
This region defines the tumor core (TC), which comprises the combination of NC, NE
and ET. Note that the TC describes what is typically resected during surgery.
3) Region 3 – Enhancing tumor (ET)
The ET region biologically represents regions of contrast leakage through disrupted
blood-brain barrier.
We evaluate the 3D volume overlap by computing the Dice similarity coefficient
(DSC =

2∙|A∩B|
)
|A|+|B|

[89], where 𝐴 and 𝐵 represent the segmentation labels of a given method

and the manually annotated (i.e., ground truth) labels. The DSC value ranges in [0,1],
where 0 represents that the two comparing regions do not have any overlap and 1 means
that the regions are identical.
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3.6 Results
3.6.1 Experiment with Feature Fusion-Based Method
To solve the biophysical brain tumor growth model using LBM, three parameters
need to be considered: diffusion coefficient 𝐷, proliferation rate 𝜌 and simulated days 𝑡.
The diffusion coefficient and proliferation rate are variable to the model. Choosing a
value for these variables is challenging. The values we used for 𝐷 is within [0.02,
1.5] 𝑚𝑚2 /𝑑𝑎𝑦, and 𝜌𝜖[0.002, 0.2]𝑑𝑎𝑦 −1 , after considering the available literature [41].
Figure 11 shows an example of longitudinal tumor growth using the proposed method
and as depicted by ground truth labels in a single slice for a patient in the BraTS 2015
dataset.
We then apply the tumor growth model to real patient data from the BraTS dataset,
where each patient’s scan includes information of all sub-regions, i.e., NC, ED, NE, and
ET. We simulate all these abnormal tissues separately, and then fuse them all into the
final label map of the patient. Parameters vary among the various tissues [41]. By using
the LBM model, we obtain the cell density patterns for the NE, ET, and the WT tissues,
respectively. Note that the WT comprises all sub-regions including ED and NC.
Following previous work [17], we use a total of 30 features including fractal, mBm,
intensity and intensity difference among MRI modalities.
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For specification of Eq. 12, label 𝑐 ∈ (0, 1, 2, 3, 4) which represents background, NC,
ED, NE, and ET, respectively. 𝐾 is empirically chosen as 20, and number of random
features is 4, which is approximately equal to the square root of total number of features.
Addition of cell density as a feature, results in 30 features (density of NC, ED, NE, and
ET) extracted from each MRI slice. Figure 12 gives an illustrative example of comparing
two cases between tissue segmentation obtained before and after adding cell density as a

Figure 11. An example of longitudinal tumor growth by using proposed method for

one slice of patient 439. (top left) Simulated NC with D = 0.052, ρ = 0.01. (top
middle). ED with D = 0.06, ρ = 0.009. (top right) NE with D = 0.03, ρ = 0.014.
(bottom left) ET with D = 0.05, ρ = 0.01. (bottom middle) Fused label and (bottom
right) ground truth of the second scan data.

41
feature type for a patient.

Figure 12. Examples of tumor segmentation prediction by using the proposed method.
(Left column) Without cell density feature, (middle column) With cell density feature,
and (right column) the ground truth of second time scan.
We evaluate the performance of the proposed method and compare the DSC to the
segmentation prediction without cell densities features (Figure 13). We further evaluate
the statistical significance of the obtained results using paired t-test for all patients. The
𝑝-values for segmentation prediction obtained with and without inclusion of the cell
density feature show statistical significance for WT, TC, and ET tissues (Table 2). The
paired t-test analysis shows that fusion of tumor growth pattern with texture and intensity
features offers a significant improvement in the segmentation prediction of TC and ET
tissue regions. However, the statistical analysis does not suggest significant improvement
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for the WT tissue. We hypothesize that the reason for this is that the WT label, which

Figure 13. Comparison of tumor growth prediction segmentation using proposed
method. Vertical line and “+” indicates the median and the mean, respectively.
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represents the abnormal T2-FLAIR signal, is well-segmented by the originally applied
method (GB, or RF) and hence there is not substantial significant improvement offered
by the proposed method.
Table 2. Paired t-test for comparison of the volume between without and with cell density
by using RF only to predict the tumor segmentation labels in timepoint 2, using data from
timepoint 1.
Result w/o cell density
Result with cell density
𝑝-value

DSCWT
0.251±0.08
0.314±0.16
0.150

DSCTC
0.229±0.08
0.332±0.065
0.0002

DSCET
0.311±0.101
0.448±0.076
0.0002

3.6.2 Experiment with Joint Label Fusion-Based Method
We apply the joint label fusion-based brain tumor segmentation prediction to process
data from all nine patients at timepoint 2 (post-op scans). To evaluate the performance,
we use a Leave-One-Out cross-validation schema to compute the DSC of segmentations
at timepoint 2 from the proposed method and compare to the ground truth and to
segmentations generated by GB [48, 86] (Figure 14). An example segmentation
prediction result is shown in Figure 15. From the collective summary of comparisons, we
note that the proposed method offers better results than GB alone. The result DSC for the
proposed method is 0.850±0.055 for WT, 0.836±0.041 for TC, and 0.837±0.0074 for
ET.
We also statistically evaluate the segmentation prediction results using ANOVA and
the resulting 𝑝-values are shown in Table 3. The joint label fusion-based (JLF) method
offers statistically significant improvements on tumor segmentation performance for the
WT and ET regions, when compared to the results of the GB method. The overall
performance is better than GB and RF across all patients, as shown in Figure 14.
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Figure 14. DSC comparison results among GB, RF, and proposed method (JLF) at
time 2. Vertical line and “+” indicates the median and the mean, respectively.
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Figure 15. An example of label fusion-based application. The first (top) row denotes
the input brain scans. Rows 2-4 illustrate shows the axial, sagittal, and coronal views,
respectively, of the T1c input can overlaid with GB, RF, JLF and GT labels.
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Table 3. Performance of 3D brain tumor growth prediction segmentation.
WT
TC
ET
Average DSC by GB 0.810±0.095
0.829±0.062
0.796±0.104
Average DSC by RF
0.852±0.063
0.812±0.074
0.851±0.083
Average DSC by JLF 0.850±0.055
0.836±0.041
0.837±0.0074
Median DSC by GB
0.8177
0.8266
0.7557
Median DSC by RF
0.8369
0.843
0.8743
Median DSC by JLF
0.8544
0.8372
0.81
0.047
0.579
0.023
𝑝-value (GB and JLF)
In addition, we also compare the proposed work with BraTumIA (BTIA) [49], a stateof-art tool that has been previously used for brain tumor segmentation in longitudinal
scans. We applied BraTumIA to the patient data used in our experiments and the obtained
results shown the superiority of our proposed approach (Table 4). Results for all
experiments are also given in false positive and false negative rates (Appendix B).
Table 4. Longitudinal tumor segmentation comparison of average DSC between
BraTumIA [49] and JLF.
BraTumIA [49]
JLF

𝐷𝑆𝐶𝑊𝑇
0.761±0.104
0.850±0.055

𝐷𝑆𝐶𝑇𝐶
0.703±0.186
0.836±0.041

𝐷𝑆𝐶𝐸𝑇
0.732±0.140
0.837±0.075

3.7 Discussion
In this Chapter, we propose two methods for longitudinal brain tumor segmentation
prediction, in longitudinal mMRI. Feature fusion using RF and tumor cell density offers
improved performance for predicting longitudinal tumor growth. Specifically, this
method shows significant prediction improvement of TC and ET abnormal tissues, while
there is no significant improvement for WT tissue. On the other hand, the joint label
fusion using RF and GB labels shows improvement on WT and ET abnormal tissues over
that of the GB labels alone. Note due to availability of limited number of longitudinal
tumor growth patient cases used in this study, the segmentation prediction performance is
not optimal for all possible types of abnormal tissue.
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CHAPTER 4
BRAIN TUMOR GRADING USING PHENOTYPE AND PROTEOMICS
INFORMATION

4.1 Chapter Overview
This chapter proposes a joint analysis of histopathology and proteomics patient data
using DNN for improving brain tumor grade type and subtype classification following
new WHO tumor grade criteria. The work utilizes digital pathology images and four
pieces of proteomics information (IDH, X1p/19q codeletion, ATRX, and MGMT) to
obtain improved tumor classification accuracy. In addition, a specific shape-based
measure for abnormal cell nuclei known as cellularity [90] is investigated for its efficacy
in tumor subtype classification. Cellularity is used to indicate the probability of cancerous
cells of the whole slide image (WSI). Specifically, our work discovers the potential role
of cellularity in histopathology image and IDH type in proteomics data for subtype
classification within Grade III brain tumor.

4.2 Introduction
Gliomas are primary brain tumors that originate from glial cells. Survival period of
the glioma patients is highly related to the tumor type and grade. According to a recent
report, five-year (2011- 2016) survival rate is 94.1% for pilocytic astrocytoma yet it is
only 5.6% for glioblastoma [2]. Overall, 94.1% of patients with pilocytic astrocytoma
(LGG grade II), 57.6% of patients with anaplastic oligodendroglioma (LGG grade III),
30% of patients with anaplastic astrocytoma (LGG grade III) survived five years after
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diagnosis [2]. Therefore, accurate tumor classification and grading may help in making
proper treatment planning and assessing overall prognosis in clinical practice.
Prior to 2016, the World Health Organization (WHO) standard for brain tumor
classification has been based on only the histologic appearance in pathologic slides.
Tumor grade is classified according to the microscopic similarities with different putative
cells of origin and differentiation level [4]. The histological features of mitotic activity,
microvascular proliferation and necrosis are used when grading the diffuse glioma. There
are many studies in the literature for tumor grading using histopathology images [91-93].
As only histopathology data for tumor grading is no longer accurate and efficient, a new
CNS brain tumor grade classification standard has been released by WHO in 2016 [4].
Due to the drawbacks of tumor grading based only histology, proteomics information has
recently been used for tumor classification [53-56]. With the new standard for tumor
grading, isocitrate dehydrogenase (IDH) mutation in proteomics information is identified
as one of the major criteria [53].
Computational methods provide an additional method in analyzing proteomics and
histopathology data. There are only few works that focus on tumor grade classification
using both histopathology and proteomics information in the literature. Most of the tumor
classification and grading manuscripts still focus on non-invasive structural MRI and
proteomics information [94-96]. These works have specific limitations. First, for the
structural MRI-based methods, the authors need to extract manually identified features
before further analysis. Secondly, they may classify gliomas by using MRI and
proteomics information separately. There has been intense work in literature using Deep
Neural Network (DNN) for brain tumor classification [92, 97-99]. DNN is capable of
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automatically learning features from raw data for classification of tumor types. A typical
convolutional neural network consists of an input layer, multiple hidden layers, and an
output layer. The hidden layers typically include convolution layers, activation function
layers, pooling layers, and fully connected layers.

4.3 Background
CNS tumor grade classifications has been an intense research area. Based on the
different types of patient data, tumor classification and grading methods are generally
categorized in two groups: digital pathology-based, and proteomics-based methods.
There have been a few works in non-invasive MRI-based tumor grading. Zacharaki et al.
use a support vector machine (SVM) based machine learning method to classify brain
tumor on combining conventional anatomic MRI and perfusion MRI. Their method
achieves 96% accuracy for distinguishing LGG and HGG using leave-one-out cross
validation [100]. Fusun et al. use a SVM to grade gliomas based on multi-parametric
MRI [95]. In [96], authors use a machine learning based method for molecular subtyping
of gliomas by analyzing the radiomics data. However, these methods may not be suitable
for clinical use [100-103].
4.3.1 Digital Pathology-Based Method
Digital pathology images have been the primary source for tumor grade classification
prior to the most recent WHO grade criteria. There are many works on tumor
grading/classification in the literature. Yonekura et al. propose an improved disease stage
classification using a convolutional neural network for glioma histopathology images
[104]. They obtain classification accuracy is 87.15% for differentiating LGG and HGG.
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Ertosun et al. propose a gliomas grading method using convolutional neural networks
(CNN) [98], which achieves good results. Even though histopathology-based tumor grade
classification of low-grade gliomas has been used widely, it is not suitable to predict
clinical outcomes due to high intra- or inter-observer variability [91, 105]. Because of
inaccurate tumor grade classification using only histopathology information, clinicians
usually consider genetic classification to guide clinical decision-making for treatment
planning and management of patients with brain tumors [53, 56, 106, 107].
4.3.2 Proteomics-Based Method
Proteomics studies of brain tumors have been critical to understand the proteomics
underpinnings of neoplasms. For infiltrating gliomas, proteomics classification are more
reliably reflected underlying tumor biology than traditional morphology [108].
proteomics underpinning of primary central nervous system has changed the perspective
to tumor diagnosis and classification [108]. Few works study tumor grade by introducing
proteomics information. IDH mutation has shown to be present in about 80% of LGG
grade II and grade III and secondary HGG [109]. IDH 1/2 encodes the Krebs or citric
acid cycle family of metabolic enzymes [54]. Furthermore, patients with IDH-mutated
gliomas have significantly longer survival than for those with IDH wild-type tumor [55].
On the other hand, there are some works on tumor grading using histopathology data in
the literature. Kong et al. proposed a computer-aided classifying grade of neuroblastic
differentiation on whole-slide histology images [110]. Using a method called sequential
floating forward selection (SFFS), the authors first segment nuclei, extract hand-crafted
features, apply feature selection method and finally use k-nearest neighbor for
classification. Barker et al. propose an automated brain tumor type classification in
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whole-slide digital pathology images using local representative tiles [93]. In another
work, nuclei segmentation is obtained by using hysteresis thresholding and
watershedding, feature selection, and an Elastic Net Classification for brain tumor
grading. In [92], Mousavi et al. proposed an automated brain tumor grade discrimination
based on spatial domain analysis. The authors developed a method for cell segmentation
and a customized operation of spatial and morphological filters to identify microvascular
proliferation, then apply a hierarchical decision for LGG and HGG classification.
Molecular mutation, such as IDH 1/2, ATRX, 1p/19q codeletion, TERT, and MGMT have
also been studied for glioma proteomics classification [58].
Following the relationship between IDH mutation status and glioma classification,
Chang et al. utilized a residual convolutional neural network to determine IDH status in
low- and high- grade glioma from MR imaging [111]. By analyzing Japanese glioma
patients with IDH mutations, Mukasa et al. found that IDH mutation with intact 1p/19q is
useful when assessing prognosis of LGG grade III patients [57]. A strong association has
been found between IDH canonical mutations and the alpha thalassemia/mental
retardation syndrome X-linked (ATRX) mutation, whereas X1p/19q codeletion and ATRX
loss barely exists simultaneously [112]. Leeper et al. proposed a better proteomics
classification method using X1p/19q codeletion, IDH mutation, and ATRX for grade II
diffuse glioma [113]. In addition ,the O6-methylguanine-DNA methyltransferase
(MGMT) is believed to have been associated with longer survival in patient with
glioblastoma (HGG) [114]. In Reference [107] the authors study glioma groups based on
X1p/19q, IDH and telomerase reverse transcriptase (TERT) promoter mutation in tumors.
They found that proteomics groups are interpedently associated with overall survival
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among LGG grade II and grade III patients, but not among patients with glioblastoma.
All these studies suggest that there is a lack of methods using both histopathology and
proteomics data for tumor type and subtype classification as suggested by the latest WHO
guidelines. Consequently, the proposed method in this work analyzes pathology images
and proteomics data using DNN for achieving an improved tumor type and subtype
grading.

4.4 Methodology
In the section, we discuss image pre-processing (color normalization), cellularity and
the proposed method using DNN for glioma type and subtype grading.
4.4.1 Pre-processing of Histopathology Data
In histopathology, tissue sample images are commonly stained by a combination of
hematoxylin and eosin (H&E). Hematoxylin binds to nuclei with a bluish-purple, and
eosin stains acidophilic proteins with a red-pink. The stained tissue biopsies and
microarrays are easy sharing and analyzing with computer algorithm [115]. However,
due to the color corresponding to difference in slide scanners, there is an undesirable
variation in color, which results in image interpretation difficulty. Color normalization
can help both pathologists and software in comparing different tissue sample by
standardizing image appearance. In this work, we utilize a structure-preserving color
normalization and sparse stain separation proposed in [116] to normalize H&E stained
tissue images. A given RGB image is converted to an optical density (𝑋) based on BeerLambert law, then the stain separation is decomposed by non-negative constraints on the
stain density (𝐿) and color appearance matrix (𝑊), which yields,
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1

𝑚𝑖𝑛 2 ‖𝑋 − 𝑊𝐿‖2𝐹 + 𝜆 ∑𝑟𝑗=1‖𝐿(𝑗, : )‖1 ,

(23)

𝑊, 𝐿 ≥ 0, ‖𝑊(: , 𝑗)‖22 = 1,

(24)

𝑊,𝐿

subjects to,

where 𝜆 is sparsity and regularization parameter. 𝑟 is the number of stains.
Then, the stain separation of source (𝑋𝑠 ) and target 𝑋𝑡 images are needed to factorize into
color appearance and stain density map (𝑊𝑠 𝐿𝑠 and 𝑊𝑡 𝐿𝑡 ). To preserve structure color
normalization, we normalize the color appearance of a source image 𝑠 to a target image 𝑡.
Finally, we combine a scaled version of the density map with color appearance of the
target image to create the normalized source image. It can be expressed as:
𝐿 (𝑗,:)

𝑠
(𝑗, : ) = 𝑅𝑀
𝐿𝑛𝑜𝑟𝑚
𝐿𝑅𝑀 (𝑗, : ), 𝑗 = 1, ⋯ , 𝑟,
𝑠
𝐿 (𝑗,:) 𝑡

(25)

𝑠

𝑋𝑠𝑛𝑜𝑟𝑚 = 𝑊𝑡 𝐿𝑛𝑜𝑟𝑚
,
𝑠

(26)

where 𝐿𝑅𝑀
= 𝑅𝑀(𝐿𝑖 ) ∈ 𝑅 𝑟×1 , 𝑖 ∈ 𝑠, 𝑡 and RM computes the pseudo maximum of each
𝑖
row vector at 99%. The registered normalized source image is recovered by:
𝐼𝑠𝑛𝑜𝑟𝑚 = 𝐼0 𝑒𝑥𝑝(−𝑋𝑠𝑛𝑜𝑟𝑚 ),

(27)

where 𝐼0 is the illuminating light intensity on the sample [116].
Figure 16 shows three examples of color normalization for different types of H&E tiles.
Case A is a LGG grade II that shows oligodendroglioma with mutant IDH, wild-type
(WT) ATRX, X1p/19q codeletion and Methylated MGMT. Case B is a LGG grade III
which has astrocytoma with mutant IDH, mutant ATRX, non-codeletion of 1p/19q, and
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unmethylated MGMT. Case C is a HGG that contains glioblastoma with WT IDH, WT
ATRX, non-codeletion of X1p/19q, and unmethylated MGMT.
4.4.2 Cellularity in Histopathology Data

Figure 16. Three color normalization instances representing LGG grades II, III, and
HGG. Top row showing original H&E, and bottom row showing the normalized H&E
using proposed method. Column from left to right: case A (LGG grade II), case B (LGG
grade III), and c (HGG).
Assessment of cellularity is an important component of tumor burden assessment.
Cellularity is usually estimated by pathologists in clinical practice and has been used in
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breast cancer analysis [90, 117]. The cellularity of any given image is computed as the
ratio of the area of a cancerous cell over the whole image area. Nuclei segmentation
followed by dilation of the cancerous cell is needed for computing the cellularity, then
the cellularity is calculated by area of dilated cancerous cell area over the whole image
area. Morphological dilation step is applied on the malignant nuclei to expand the
malignant cancerous cells that may account for the presence of cytoplasm around each
nucleus [90, 118]. The dilation size is set as 11 as in [90, 118]. Cellularity value ranges
within 0 and 1. In our case, the dilation size is empirically set as 12. In general, LGG
grade II is defined to have a small cellularity value while HGG has a large value of
cellularity. Nuclei segmentation is implemented by using a deep learning based UNet
method [119].
4.4.3 Proposed Tumor Grading Method
We use a cascaded convolutional neural network as the underlying model for tumor
grading [11]. A multi-class (LGG grade II, LGG grade III, and HGG) classification
problem is posed as step-wise binary classification problem. In the first step, we
discriminate HGG and LGG using a regular DNN. For LGG, we further apply a residual
neural network (ResNet [120]) to distinguish between LGG II and III. The proposed
pipeline is shown in Figure 17. Note as our proposed method utilizes both digital
pathology images and proteomics information, the resulting pipeline uses two types of
DNNs. Finally, cellularity information is introduced to improve tumor type and subtype
grading performance.
Accurate classification of LGG grade II from LGG grade III is more challenging as
the two tumor types have very similar histopathologic appearance. The DNN model used
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for LGG grade II/III is similar to that of LGG/HGG, however, the network contains more
layers which may capture a subtle differences between two similar tumor grades. A
ResNet architecture is used at the second step. The structure details of these DNNS are

Figure 17. The pipeline has two parts: cellularity and grade classification. In
cellularity part, nuclei segmentation of the input H&E is implemented using UNet
architecture with Multi-Organ nuclei segmentation data set. Cellularity is computed by
using the dilated image. For grade classification part, we use a cascaded DNN for
distinguish tumor grade. The first DNN (DNN1) is to classify HGG and LGG, and the
second DNN (DNN2) is to distinguish LGG II and III. In DNN module, we attach the
proteomics information (IDH, ATRX, X1p/19q codeletion and MGMT) to the fully
connected layer. For Resnet, there is a skip connection within each block.
listed in Table 5.
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Table 5. Deep neural network structures for CNN and ResNet. We show the data size of
each layer. In each convolution block, it has 1 convolution layer, 1 ReLU layer, and 1
max pooling layer. We construct a more complex neural network for differentiating LGG
II/III by considering the much similarity within them.
Layers

Output size of CNN

Output size of ResNet

Input
Conv. block 1
Conv. block 2
Conv. block 3
Conv. block 4
Conv. block 5
Conv. block 6
Conv. block 7
Conv. block 8
Conv. block 9
FC layer 1
FC layer 2
FC layer 3

512*512*3
256*256*8
128*128*16
64*64*32
32*32*64
16*16*128
8*8*256
4*4*512
8192
128
2

512*512*3
256*256*8
128*128*16
64*64*32
32*32*64
16*16*128
8*8*256
4*4*512
2*2*512
1*1*1024
1024
128
2

4.5 Experiments and Results
4.5.1 Data
We use 96 public digital diagnostic whole slide hematoxylin and eosin (H&E) stained
histopathology images with proteomics and clinical information from The Cancer
Genome Atlas (TCGA). The 96 whole slide image (WSI) contains 28 LGG grade II, 36
LGG grade III and 32 HGG. Each WSI can be larger than 1 GB. In order to process this
large size image, we divide the WSI into multiple tiles with size 1000 × 1000.
Therefore, we have an overall 96 tiles for the study. We select one tile as a reference,
then apply color normalization for the rest of the tiles, so that all tiles have a similar color
appearance that preserves original structure. For nuclei segmentation, the training H&E
straining data is obtained from Multi-Organ nuclei segmentation challenge, which
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contains 30 images and around 22000 nuclear boundary annotations for several organ
tissues [65, 121].
To evaluate the proposed method, we use 8-fold cross validation. The dataset is
randomly split as training and testing data based on tumor grade of LGG grade II, LGG
grade III, and HGG with ratio 8:2. Moreover, in order to increase data sample, we crop
sub-regions of patches with size of 512 × 512. In addition, we also apply data
augmentation techniques (random rotation of 90° , 180° , 270° , random flipping image
along axis, and random scaling image by 0.95~1.1) to increase the number of training
samples.
In our experiments, we consider IDH1/2, ATRX, X1p/19q, and MGMT as the
proteomics information. The proteomics information distribution used in this work is
listed in Table 6. There are four histologic glioma subtypes in the experimental data:
astrocytoma (AA), oligoastrocytoma (OA), oligodendroglioma (OD), and glioblastoma
(GBM). It is worth noting that oligoastrocytoma is strongly discouraged in new WHO
classification [4].
Table 6. Proteomics data distribution of patient data used in this work.
Proteomics
IDH
ATRX
X1p/19q
MGMT

Type
Mutant
Wild-type
Mutant
Wild-type
N/A
Non-codeletion
Codeletion
Unmethylated
Methylated
NA

LGG
grade II
25
3
14
13
1
22
6
4
24
0

LGG
grade III
27
9
14
22
0
29
7
9
27
0

HGG
1
31
0
17
12
32
0
13
8
11
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4.5.2 Experiments
First, we compute the cellularity feature as shown in Figure 18. The Figure shows
three examples of cellularity. In general, patients with HGG have high value of
cellularity, and small cellularity value for low-grade patients.

Figure 18. Three examples of tumor cellularity. Column one, two, three
are color normalized image, segmentation, dilated segmentation image,
respectively. Row1, Row2, and Row 3 are showing LGG grade II, LGG
grade III, and HGG, respectively. Cellularity of Row 1, 2, and 3 are
0.4972, 0.4402, and 0.7582, respectively.
As discussed above we use a cascaded convolutional neural network for pairwise
tumor grade classification. The proposed DNN is implemented using PyTorch 1.0 on
high-performance clustering with Nvidia V-100 GPU. The minibatch size is set as 2 as
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the tile size is large and maximum training epoch is set as 80. We use a binary crossentropy as the objective function. In training phase, we minimize the cross-entropy loss
[122] to optimize the model as follows:
(28)

𝑙𝑜𝑠𝑠 = − ∑∀𝑥 𝑝(𝑥) 𝑙𝑜𝑔(𝑞(𝑥)),

where 𝑝 is the true distribution, and 𝑞 is the estimated distribution of class. In training
phase, we use Adam [123] optimizer with initial learning rate of 𝑙𝑟0 = 0.001, and the
learning rate (𝑙𝑟𝑖 ) is gradually decreased as:
𝑖

𝑙𝑟𝑖 = 𝑙𝑟0 ∗ (1 − 𝑁)0.9 ,

(29)

where 𝑖 is epoch counter, and 𝑁 is a total number of epochs in training.
4.5.3 Tumor Type Classification
To investigate the impact of networks and cellularity, we compare the classification
performance by using different network with and without cellularity. The average of
accuracy over 8-fold cross validation is shown in Table 7.
Table 7. Performance of different networks with/without cellularity to tumor
classification.

Tumor type
HGG vs LGG
Grade II vs III

Cellularity
information
No cellularity
Cellularity
No cellularity

CNN

ResNet

94.91%
95.34%
67.71%

95.18%
94.42%
69.06%

Cellularity
66.80%
76.54%
Table 7 shows that the type of network and cellularity does not have noticeable
impact on discrimination of HGG versus LGG. In comparison, cellularity shows
improvement in the ability of ResNet to capture subtle difference between grade II and
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III, and may help to significantly improve the classification accuracy for these two tumor
types. The confusion matrix of the proposed method for ResNet with cellularity is shown
in Table 8.
Table 8. Confusion matrix of the proposed method using image patches. In the method,
we use CNN for discriminating HGG and LGG, and ResNet for distinguishing LGG
grade II and III. Both are with cellularity.

Predicted class

Actual class

LGG grade II
LGG grade III
HGG

LGG grade II
601
154
1

LGG grade III
371
1107
89

HGG
36
36
1063

This experiment investigates effect of different combinations of patient data using 8fold cross validation for tumor type classification. The result is shown in Table 9. The
regular CNN model offers the best performance when all information (pathology image,
proteomics information, and cellularity) is considered with the best performance of
95.34% ± 4.67% for discrimination of LGG vs HGG. ResNet offers the best result with
76.54% ± 7.24% for classification of LGG2 and LGG3.
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Table 9. Performance comparison by applying proposed method for different data
information.

Tumor Type

Pathology, proteomics and
radiology information
Pathology
Pathology + proteomics

HGG-LGG
Pathology + cellularity
Pathology + proteomics +
cellularity
Pathology
LGG grade
II-LGG grade
III

Pathology + proteomics
Pathology + cellularity
Pathology + proteomics +
cellularity

Network type
CNN
CNN
CNN
CNN
ResNet
ResNet
ResNet
ResNet

Glioma grading
Accuracy
92.48% ±
5.30%
94.41% ±
3.69%
93.43% ±
4.95%
95.34% ±
4.67%
64.84% ±
7.57%
68.89% ±
8.87%
66.23% ±
6.11%
76.54% ±
7.24%

4.5.4 Tumor Subtype Classification
In this experiment, we study the effect of cellularity feature in discriminating between
IDH mutation status that may indicate glial aggressiveness within a specific type of brain
tumor. The results show potential correlation between cellularity and IDH types as shown
in Table 10. It shows the average cellularity value and variance among different grade
gliomas.
For LGG grade III and HGG, cellularity of glioma patient with Wild-type IDH is
higher that of Mutant IDH. Note that cellularity of Wild-type IDH of LGG grade III
(0.45) is close to that of Mutant IDH of HGG (0.44). Cellularity of glioma patient with
Grade III, IDH 1/2 wild-type acts aggressively as that of glioblastoma patient with IDH
1/2 mutant type. This result suggests that one may predict IDH type, and hence, the tumor
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subtype (aggressiveness) using the cellularity information. Table 10 also shows that
cellularity of patient with IDH-mutant type is higher than that of wild type for LGG grade
II.
Table 10. Average cellularity and variance for all grade gliomas with IDH type in our
data.
Tumor grade

IDH mutant-type

IDH wild-type

LGG grade II

0.3769±0.0761

0.3908±0.1029

LGG grade III

0.4012±0.0834

0.4500±0.0920

HGG

0.4419

0.5580±0.1014

4.5.5 State-of-the-art Comparison
We compare our result in this work with existing works in the literature as shown in
Table 11. Note that the comparison is qualitative rather than quantitative as the patient data,
methods, and number of patients are all different for these works. The comparison Table
shows that for tumor type classification, our work is comparable in differentiating HGG vs
LGG, and offers the best performance on distinguishing LGG grade II vs LGG grade III.
With addition of proteomics information, our proposed method offers the highest accuracy
for LGG grade II vs. grade III classification.
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Table 11. Performance comparison with state-of-art. Accuracy percentage in bold is the
best result in the comparison. “-” sign indicates the data is non-available.

Authors

Image type

Mohana Priya
K, et al.[97]

MRIs

Mehmet G.
Ertosun, et al.
[98]

WSI

Ajay
Basavanhally et
al. [124]

WSI

Mousavi, et al.
[92]

WSI

Jocelyn Barker,
et al. [93]

WSI

Aditya Bagari,
et al.[125]

MRI+Pathology

Shamim Reza,
et al. [94]
Our proposed
method

Number
of
patients

Method

Accuracy
of HGG
vs LGG

SVM

78.26%

CNN

96%

Multifieldof-view
classifier

93%

138

Decisiontree

84.7%

302

Elastic
Net
classifier

93.1%

CNN

-

Random
forest

86%

231
7

126

MRI+
proteomics

20
66
66

WSI+
proteomics
WSI+
proteomics

-

Accuracy
of LGG
II vs
LGG III
-

-

SVM
96

Crossvalidation

CNN

71%
72%
-

-

5
-

90%

10
10

93%
93.11%

-

8

76.54%

We further compare the preformation of tumor subtype classification using our
proposed method to the state-of-the-art. We achieve tumor subtype classification accuracy
71.42%, 62.31%, 68.18%, 96.77% for astrocytoma (AA), oligoastrocytoma (OA),
oligodendroglioma (OD), and Glioblastoma (GBM), respectively. In comparison the
authors in [126], report accuracy of 65.85%, 46.50%, 60.26%, and 95.54%, for the same
tumor subtypes as shown in Table 12. Note unlike [126] our proposed method in this work
report both tumor type and subtype classifications following the new WHO criterion.
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Table 12. Tumor subtype classification comparison to state-of-the-art.
AA

OA

OD

GBM

AO

Work in [126]

65.85%

46.50%

60.26%

95.54%

25%

Our method

71.42%

62.31

68.18%

96.77%

-

4.6 Conclusion
In this Chapter, we propose a deep learning-based method for improving brain tumor
type and subtype grading using both pathology and proteomics data following the new
2016 WHO classification. The classification method integrates a cellularity feature which
is derived from morphology of histologic images to improve classification performance.
The experiments show that while type of DNN may not be critical in discrimination of
low-grade from high-grade glioma, DNN may have significant impact for discriminating
grade II versus grade III. Moreover, we investigate the impact of proteomics and
cellularity information on glioma grading. An interesting finding of this work is that the
cellularity features show promise in prediction of subtype of LGG grade III with IDH
mutation. Specifically, for patient with LGG grade III, cellularity of wild-type IDH is
higher than that of mutant-type, suggesting that cellularity feature obtained from
pathology image may be used to classify more aggressive wild-type IDH subtype of LGG
grade III. These findings may be beneficial to tumor prognosis and treatment planning. In
the future, we plan to apply the proposed method for larger patient data to validate the
findings in this study.
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CHAPTER 5
BRAIN TUMOR SEGMENTATION, TUMOR SUBTYPE CLASSIFICATION,
AND SURVIVAL PREDICTION USING DEEP NEURAL NETWORK

5.1 Chapter Overview
This chapter proposes context-aware deep learning for brain tumor segmentation,
subtype classification, and overall survival prediction using structural multimodal
magnetic resonance images (mMRI). We first propose a 3D context-aware deep learning,
that considers uncertainty of tumor location in the radiology mMRI image sub-regions, to
obtain tumor segmentation. We then apply a regular 3D convolutional neural network
(CNN) on the tumor segments to achieve tumor subtype classification. Finally, we
perform survival prediction using a hybrid method of deep learning and machine
learning. To evaluate the performance, we apply the proposed methods to the Multimodal
Brain Tumor Segmentation Challenge 2019 (BraTS 2019) dataset for tumor segmentation
and overall survival prediction, and to the dataset of the Computational Precision
Medicine Radiology-Pathology (CPM-RadPath) Challenge on Brain Tumor
Classification 2019 for tumor classification. The online evaluation performance suggests
that the proposed method offers robust tumor segmentation and survival prediction,
respectively. Furthermore, the tumor classification results in this work was ranked second
place in the testing phase of the 2019 CPM-RadPath global challenge.

5.2 Background
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Gliomas are the most common primary brain malignancies, with varying degrees of
aggressiveness, variable prognosis and various heterogeneous regions [1]. In the US, the
overall average annual age-adjusted incidence rate for all primary brain and other central
nervous system (CNS) tumors has been reported as 23.03 per 100,000 population during
2011-2015 [2]. For patients with malignant tumors, the estimated five- and ten- year
relative survival rates are 35.0% and 29.3%, respectively, according to the report from
2011-2015 [2]. The median survival period of patients with glioblastoma (GBM) is about
12-15 months [5]. Diagnosis of tumor subtype and grade is vital for treatment planning
and prognosis of the patients. According to a 2016 report of World Health Organization
(WHO), classification of tumors in the CNS is based on both phenotype and genotype
(i.e., IDH mutation and X1p/19q codeletion status) [4]. However, structural imaging such
as magnetic resonance imaging (MRI) is continued to be used for identifying, locating,
and classifying brain tumors [13, 100, 127, 128]. Tumor subtypes include diffuse
astrocytoma, IDH-wildtype/-mutant, oligodendroglioma, IDH-mutant and 1p/19qcodeleted, glioblastoma, IDH-wildtype, etc. [4]. Traditional machine learning-based
methods, such as support vector machines (SVM), k-nearest neighbors algorithm (KNN),
and random forest (RF) are generally utilized for brain tumor analysis [14, 15, 31, 94,
129-131]. However, these methods have the common limitation of hand-crafted feature
extraction in the modeling phase.
Deep learning-based methods overcome the drawback of hand-crafted feature
extraction. Deep learning has made it possible to build large-scale trainable models that
have the capacity to learn the optimal features required for a given task. Deep learning is
powerful and outperforms traditional machine learning in many fields, such as computer
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vision [132-134], medical image segmentation [119, 135], and speech recognition [136].
Deep learning is fundamentally composed of a deep neural network structure with several
layers. An artificial neural network utilizes a backpropagation algorithm to decrease the
error between the prediction and ground truth. However, training artificial neural network
models becomes more difficult as the number of layers increase [137]. Deep neural
network training has been feasible since the mid-2000s, which brought about increased
availability of large datasets and hardware improvements.
As a standard protocol for brain tumor characterization, MRI is able to capture a
diverse spectrum of tumor phenotypes [138]. Multimodal MRI (mMRI) provides
comprehensive tumor information. For example, post-contrast T1-weighted (T1ce)
images are well-known to be correlated with blood brain barrier (BBB) disruption, while
T2-weighted (T2) and T2 Fluid Attenuated Inversion Recovery (FLAIR) images are wellknown for capturing tumor margins and peritumoral edema [138]. This suggests that the
phenotypic differences at the cellular level are also reflected in the imaging phenotype
(appearance and shape). While mMRI captures comprehensive brain tumor information,
extracting this information through brain tumor analysis, such as tumor segmentation,
remains challenging because of the similar phenotypic appearance of abnormal tissues in
mMRI images. Figure 19 shows the intensity distribution of three types of abnormal brain
tissues in T1, T1ce, T2, and FLAIR images for a representative case. These intensity
distributions are highly similar for tumor tissues for all patients in this study. While on
T1ce image, enhancing tumor (ET) is easily separable from others, the necrosis (NC) and
peritumoral edema (ED) have nearly the same intensity distribution.
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Brain tumors have been studied for many years. However, most works study tumor
segmentation, classification, and overall survival prediction independently, ignoring the
underlying relationship among these critical analysis tasks. In this work, we propose a
complete framework for brain tumor study, including tumor segmentation, subtype
classification, and overall survival prediction by analyzing mMRI via a deep learningbased neural network architecture.

Figure 19. Intensity distribution of necrosis, edema, and enhancing tumor on T1 (top left),
T1ce (top right), T2 (bottom left), and FLAIR (bottom right) images of one case.
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5.3 Methodology
There are many methods reported in the literature on brain tumor segmentation that
include intensity-based, atlas-based, deformable model-base, hybrid-based, and deep
learning-based methods [139]. Recently, deep learning-based methods offered better
performance for tumor segmentation [29, 33, 34]. For tumor classification, both noninvasive structural MRI and pathology images are utilized to classify brain tumors [126,
140, 141]. Overall survival prediction is to estimate the remaining life span of a patient
with brain tumors. Most existing work is based on traditional machine learning and linear
regression [1, 142].
Figure 20 illustrates an overview of the proposed framework. In A, there are four raw
MRI modalities: T1, T1ce, T2, and FLAIR. The raw images are pre-processed in B,
including co-registration, skull-stripping, noise reduction, etc. We then perform a z-score
normalization for the brain region only to have zero mean and unit standard deviation.
Subsequently, the proposed Context Aware Deep Neural Network (CANet) is applied to
segment tumor as shown in C. The segmentation results are shown in D. In E, a 3D CNN
is utilized to classify tumor using the segmented abnormal tissues. In F, we extract highdimensional features using front-end of the CANet, and then apply a linear regression for
overall survival prediction.
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A: Raw T1, T1ce, T2, and FLAIR

T1

T1ce

T2

FLAIR

B: Pre-processed T1, T1ce, T2, and FLAIR

T1

D: Segmentation

GT

T1ce

T2

C: CANet

Prediction

E: Tumor subtype classification

F: Survival Prediction

Figure 20. Overview of the methodology and overall work flow.

5.3.1 CNN-Based Tumor Segmentation
An overview of the proposed context-aware deep learning method for tumor
segmentation is shown in Figure 21. The proposed CANet captures global texture
features and utilizes semantic loss to regularize the training error [143] [119]. The

FLAIR
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architecture consists of encoding, context encoding, and decoding modules. The encoding
module extracts high-dimensional features of the input. The context encoding module
produces updated features and a semantic loss to regularize the model. The decoding
module reconstructs the feature maps to an output prediction, so that we compute the
difference between the reconstructed output and input images as a regularizer.

Figure 21. Overview of the proposed CANet architecture for tumor segmentation. It
consists of encoding, decoding, and context encoding modules. Encoding and decoding
module are UNet-like symmetric. Context encoding module produces semantic loss.
5.3.2 CNN-Based Tumor Classification

Figure 22. Overview of CNN-based tumor classification. At the last convolutional layer,
we apply an average pooling layer to shrink the size.
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The pipeline for tumor classification is shown in Figure 22. Overview of CNN-based
tumor classification. At the last convolutional layer, we apply an average pooling layer to
shrink the size. In this work, the segmented tumor uncertainty in subregions (ET, TC, and
WT) from the above section are used as the input of the proposed tumor classification
model. We use a regular CNN-based architecture for tumor classification. The
probabilities of tumor subregions are convolved and down sampled, then passed through
three fully connected layers to achieve classification.

5.3.3 Hybrid Method for Survival Prediction
Instead of extracting features and using a traditional machine learning approach, we
utilize the proposed CANet to extract high-dimensional features. We believe that the
extracted features from tumor segmentation are associated with overall survival. The
features are then selected using the LASSO method [144]. Finally, we apply a linear
regression to the selected features for overall survival prediction (as shown in Figure 23).

Figure 23. Pipeline of proposed method for overall survival prediction.

5.4 Experiments and Set UP
5.4.1 Data Description
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In this work, the experimental data is obtained from Multimodal Brain Tumor
Segmentation Challenge 2019 (BraTS 2019) [1, 12, 145-147] for brain tumor
segmentation and overall survival prediction and Computational Precision Medicine:
Radiology-Pathology Challenge on Brain Tumor Classification 2019 (CPM-RadPath
2019) [148] for tumor classification. The BraTS 2019 dataset includes training,
validation, and testing data. The training data has a total of 335 cases consisting of 259
HGG and 76 LGG cases. There are 102 cases obtained from The Cancer Imaging
Archive (TCIA) [149], and the rest are from private dataset. Only cases with gross total
resection (GTR) are evaluated for overall survival prediction. In addition, there are
another independent 125 and 166 cases for the validation and testing phases, respectively.
Note that, the grading information, resection status, and ground truth are privately owned
by the challenge organizer and not available for public use. For the CPM-RadPath 2019
dataset, training, validation, and testing data are also provided. There are 221, 35, and 73
cases for training data, validation data, and testing data, respectively. Ground truth is
available for only the training data. In both datasets, the multimodal MRIs have been preprocessed by the organizers following the protocol in [145]. The summary of gender
information for both training datasets is shown in Table 13.
Table 13. Experimental training data summary.
Gender
Tumor segmentation
Tumor classification
Survival prediction

Male
90
52
65

Female
76
46
41

Unknown
169
123
104

Total
335
221
210
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For segmentation, the tumor ground truth consists of one/more abnormal tissue(s):
necrosis (NC), peritumoral edema (ED), and enhancing tumor (ET). However,
performance evaluation is based on tumor sub-regions: enhancing tumor (ET), tumor core
(TC), and whole tumor (WT), where TC consists of ET and NC. WT is a combination of
TC and ED. For tumor classification, there are three subtypes: lower grade astrocytoma
with IDH-mutant (Grade II or III), oligodendroglioma with IDH-mutant, X1p/19q
codeleted (Grade II or III), and glioblastoma and diffuse astrocytic glioma with
proteomics features of globlastoma, IDH-wildtype (Grade IV). For overall survival
prediction, there are three categories: short-term (<10 months), mid-term (between 10-15
months), and long-term (>15 months).

5.4.2 Experimental Setup
All experiments in this study are performed in accordance with relevant guidelines
and regulations as approved by the institutional IRB committee at Old Dominion
University.
Experiment 1: brain tumor segmentation. A total of 335 patients are used for training,
and 125 patients are used for validation. Note that the ground truths of the validation
dataset are not available to public. At the validation and testing phases, we submit the
segmentation results to the challenge portal for BraTS 2019 Online evaluation [150]. For
the hyperparameters of the proposed context-aware deep learning, the initial learning rate
is set to 0.0001, and decays gradually to 0 at the end of training. Total number of epochs
is set to 500. The Adam optimizer is used [123] for gradient descent optimization. In
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order to prevent overfitting in the training phase, we apply the Leaky-Relu activation
function and drop out with a ratio of 0.2.
Experiment 2: brain tumor classification. There are 221 cases provided in the training
phase. We randomly take 80% of the data as training, and use the remaining 20% as our
own validation set, while maintaining the same proportion of each tumor subtype in each
set. The ground truth of the validation and testing data are privately held by the challenge
organizer. In validation phase, we submit the results for CPM-RadPath online evaluation
[26]. The hyperparameters are similar to those used in tumor segmentation, but with total
number of epochs is set to 2000. Note that for the testing phase, challenge participants are
required to submit the wrapped algorithm using Docker [151], a platform to develop,
deploy, and run applications inside containers, and tested by the organizer. The ranking is
based on the performance evaluated by the organizer. Throughout the process, only the
challenge organizer is involved in the testing evaluation.
Experiment 3: overall survival prediction. For the training phase, we randomly split
the training data into 80% and 20% sets for training and validation, respectively, while
maintaining the same proportion of cases from each risk category in each set. We then
apply the trained model to the validation data for online evaluation, and finally apply to
the testing data for ranking. The training hyperparameters are similar to that of tumor
segmentation, but with total number of epochs is set to 1000.

5.4.2 Evaluation Metrics
For tumor segmentation, dice similarity coefficient (DSC) and Hausdorff distance are
used to measure the segmentation quality [89]. DSC quantifies the overlap between two

77
subsets. It is computed as 𝐷𝑆𝐶 =

2|𝐴∩𝐵|
|𝐴∪𝐵|

[89], where A and B are two subsets. DSC of 0

means no overlap at all between the subset A and B. DSC of 1 indicates that the subsets
are perfectly overlapped. Hausdorff distance measures how far two subsets of a metric
space are from each other. It is calculated as 𝑑𝐻 (𝐴, 𝐵) = max{ℎ(𝐴, 𝐵), ℎ(𝐵, 𝐴)}, where
ℎ(𝐴, 𝐵) = max min‖𝑎 − 𝑏‖, ‖∙‖ is the norm operator [152]. Smaller Hausdorff distance
𝑎𝜖𝐴 𝑏∈𝐵

means that the two subsets are closer. For evaluation of tumor classification and overall
survival prediction, accuracy, and mean square error (MSE) are used.

5.5 Results and Contributions
5.5.1 Results
Experiment 1: brain tumor segmentation. Figure 24 shows a visual comparison of
tumor tissue segmentation in axial, coronal, and sagittal views for a representative case
for BraTS 2019. The dice similarity coefficient (DSC) and training loss changes are
shown in Figure 25. The quantification performance of the validation dataset offered by
online evaluation is shown in Table 14. In the Table, row one is the performance without
post-processing, while row two is the performance with post-processing steps that
includes small object removal and hole filling. We then test the proposed method with
BraTS 2019 dataset consisting of 166 cases with unknown tumor grade. The online
evaluation offers average DSC of 0.8133, 0.8867, and 0.84031 for ET, WT, and TC,
respectively. According to the performance comparison in Table 14, DSC of WT is 1%
lower than in the validation phase. However, DSC of ET and TC shows 6% and 4%
improvement in the testing phase. Note that the Hausdorff distance in the testing phase is
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consistently lower than that of the validation phase. These results suggest that our model
offers stable and reliable tumor segmentation results.

Figure 24. Comparison of tumor segmentation using the proposed method and
ground truth. Top row from left to right: T1ce image, segmented tumor overlaid
with T1ce in axial view, in coronal view, and in sagittal view. Bottom row from
left to right: FLAIR image, ground truth overlaid with T1ce in axial view, in
coronal view, and in sagittal view.

Figure 25. The DSC and loss changes in training stage.
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Table 14. Dice coefficient results for tumor segmentation in the validation and testing
datasets.
Phase

Postprocess
Validation
No
Validation Yes
Testing
Yes

Dice_ET
0.73856
0.77273
0.8133

Dice_WT
0.90496
0.90496
0.8867

Dice_TC
0.81496
0.81496
0.84031

Hausdorff
95_ET
4.09623
3.22012
2.22904

Hausdorff
95_WT
4.91633
4.91633
4.78833

Hausdorff
95_TC
6.80917
6.80917
4.14805

Experiment 2: tumor classification. We applied the proposed method to CPMRadPath 2019 validation dataset, then wrapped the trained model using Docker [151],
and shared with the CPM-RadPath Challenge organizer. In the testing phase, the
organizer executed the wrapped algorithm to obtain tumor subtype classification result
for the final competition. The online performance of validation (35 cases) and testing
datasets (73 cases) is shown in Table 15. In the testing phase, our result is ranked at 2nd
place [27].
Table 15. Online evaluation of tumor classification on CPM-RadPath 2019 validation and
testing datasets.
Phase

Dice

Average

Kappa

Validation

0.749

0.764

0.715

0.749

0.829

Testing

0.596

NA

0.39

0.596

0.603

Balance_acc F1_micro

Experiment 3: overall survival prediction. There are only 29 valid cases in BraTS
2019 validation dataset. Our accuracy is 0.586 using online evaluation, as shown in Table
16. In the testing phase (107 cases), the proposed method offers an accuracy of 0.439
with mean square error (MSE) of 449009.
Table 16. Survival prediction performance of the validation dataset obtained from online
evaluation.
Phase
Accuracy
Validation
0.586
Testing
0.439

MSE
79146
449009

medianSE
24362
44604

stdSE
113801
1234471

SpearmanR
0.502
0.279
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5.5.2 Contributions
To the best of our knowledge, brain tumor segmentation, tumor subtype
classification, and overall survival prediction have been studied independently, ignoring
the inherent relationship among them. In this work, we propose an integrated method for
brain tumor segmentation, tumor subtype classification, and overall survival prediction
using deep learning and machine learning methods. The specific contributions are as
follows.
First, we propose a context-aware deep learning-based method for brain tumor
segmentation. Second, we utilize a hybrid method for overall survival predication.
Specifically, we extract high-dimensional features using the proposed context aware
based convolutional neural network (CANet), and subsequently perform a traditional
machine learning method to select features, and finally apply a linear regression method
for overall survival prediction. Third, in the framework, all sub-tasks are intercorrelated
via the proposed deep learning methods, rather than studied independently.
Finally, though new WHO tumor classification criteria indicate the use of both
pathology images and proteomics information along with MRI, the proposed method is
effective in tumor classification using structural MRI data only. The proposed tumor
classification results in this work is ranked second place in the testing phase of the 2019
CPM-RadPath global challenge among 86 registered teams.
5.6 Discussion
Deep learning-based methods have been widely applied to many fields, and have
achieved start-of-the-art performance. However, brain tumor segmentation poses several
unique challenges. First, image quality has a critical impact on segmentation
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performance. For example, blurred images result in poor outcomes. Second, image preprocessing steps also have an impact on the performance. For example, intensity
normalization across cases is critical for tumor segmentation. Third, tumor tissue
heterogeneity may pose a serious challenge to the developing an effective method.
Finally, data imbalance is common and poses another intricate challenge for the use of
deep learning. Figure 26 shows the data distribution in the training phase for tumor
classification and overall survival prediction in our experiments. Cases of glioblastoma
make up more than 50% of the training data. In survival prediction, range of survival
days for mid-term survival is too narrow compared to the short- and long-term ranges,
creating a data imbalance. This data imbalance can result in misclassification. In
segmentation step, samples for edema is generally much more than other abnormal
tissues. In order to address the potential data imbalance problem in tumor segmentation,

Figure 26. Data distribution of training data for tumor classification and overall
survival prediction. (left) Frequency counts of cases for different classes of tumor.
(right) Distribution of survival days for short-term (<10 months), mid-term (between
10-15 months), and long-term (>15 months) categories.

82
we implement tumor segmentation based on MRI sub-regions, rather than using each
abnormal tissue individually.
For tumor classification, the main issue is lack of data. In this work, even though we
increase training sample size using data augmentation techniques, 221 cases may still be
insufficient number for deep learning. Similar data shortage issue also exists in overall
survival prediction. There are only 210 cases available in training phase for the CPMRadPath 2019 Challenge.
In addition to the deep learning-based approach, we also implement overall survival
prediction using a conventional machine learning method by extracting features, such as,
gray-level co-occurrence matrix (GLCM), intensity, etc., then applying LASSO to select
features, and finally using linear regression for survival prediction. We compare the result
with that of our proposed method. The comparison shows that the proposed method
achieves better performance (as shown in Table 17).
Table 17. Performance comparison of overall survival prediction using different methods
on BraTS 2019 validation dataset.
Method Accuracy
Machine
learning
0.483
The
proposed
method
0.586

MSE

medianSE

stdSE

SpearmanR

128594

20898

233919

0.044

79146

24362

113801

0.502

We also analyze the impact of gender and age on overall survival in this work. In the
training data, patients with high-grade glioma (HGG) have 461.0314 average survival
(AS) days, and 376 median survival (MS) days. Low-grade glioma (LGG) patients have
1199.8 AS with 814 MS. We investigate impact of average age (AA), median age (MA),
and gender information to average survival (AS) and median survival (MS), then
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compare the overall performance. The comparison results are shown in Table 18. For
patients with HGG, both male and female have similar average and median age (mean
age difference is less than 1 year), but males have much more AS days (520.6 versus
433), as well as MS days (426.5 versus 291). However, female patients with LGG (about
3 years younger) have longer AS period and MS period. Overall, regardless of tumor
grade, male patients that are older have fewer survival days as shown in our experimental
data.
Table 18. Age and survival days comparison based on gender.
HGG

LGG

Overall

Case

AA

MA

AS

MS

Case

AA

MA

AS

MS

Case

AA

MA

AS

MS

Male

58

60.9

60.6

520.6

426.5

7

51.7

53.8

1188.6

788

65

59.9

59.3

592.6

448

Female

31

59.3

61.5

433.1

291

10

48.1

50.1

1207.7

983

41

56.6

57.6

622

370

We also conduct statistical analysis on the impact of gender and age to overall
survival using analysis of variance (ANOVA). The p-value is shown in Table 19. The
statistical analysis suggests that gender and age are not significant for overall survival for
this dataset with only 106 patients.
Table 19. P-value using ANOVA.
Gender
Age

𝑝 − 𝑣𝑎𝑙𝑢𝑒
0.1636
0.101

5.7 Summary
In this Chapter, we investigate multiple tasks in brain tumor analysis by applying
deep learning-based methods to structural multimodal MRI (mMRI) images. These brain
tumor analysis tasks consist of tumor segmentation, tumor classification, and overall
survival prediction. We propose a context-aware deep learning method for tumor
segmentation since the context encoding module captures global context encoding
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features. The segmented tumor is then used for tumor classification by utilizing a 3D
CNN. Moreover, we also propose a hybrid method for overall survival prediction.
Specifically, we obtain high-dimensional feature extraction using front-end of the CANet,
then apply the least absolute shrinkage and selection operator (LASSO) feature selection
method to these extracted features, and finally implement an overall survival prediction
method based on the selected features.
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CHAPTER 6
CONCLUSIONS AND FUTURE WORKS
6.1 Conclusion
The overall goal of this dissertation is to obtain improved longitudinal brain tumor
segmentation, tracking, tumor grading, and patient survival prediction. The first goal of
the dissertation is to improve longitudinal brain tracking. We propose two novel methods:
feature fusion-based and joint label fusion-based. The feature fusion-based method offers
improved texture-based brain tumor segmentation in longitudinal mMRI by fusing the
tumor cell density patterns obtained from biophysical tumor growth modeling with the
stochastic texture features in a RF-based segmentation method. Statistical analysis shows
significant performance improvement for the proposed feature fusion method for the
areas of TC and ET. The JLF-based method fuses results obtained from RF with those
from GB and helps to improve GB, a state-of-the-art method on longitudinal brain tumor
segmentation.
Longitudinal brain tumor tracking not only offers tumor segmentation at current
stage, but also shows how the tumor changes over time. This may facilitate clinical
decision making, including treatment management and patient follow-up.
The second dissertation goal is to build a deep learning-based method for brain tumor
type and subtype grading, using both pathology and proteomics data, following the new
2016 WHO tumor classification criteria. The classification method integrates a cellularity
feature which is derived from the morphology of histologic images to improve
classification performance. The experiments show that, while the type of DNN may not
be critical in the discrimination of low-grade from high-grade glioma, DNN may have a
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significant impact in discriminating Grade II versus Grade III. Moreover, we investigate
the impact of proteomics and cellularity information on glioma grading. An interesting
finding of this work is that the cellularity features show promise in prediction of a
subtype of LGG grade III with IDH mutation. Specifically, for patients with LGG Grade
III, cellularity of Wild-type IDH is higher than that of Mutant type, suggesting that the
cellularity feature obtained from a pathology image may be used to classify the more
aggressive Wild-type IDH subtype of LGG Grade III that has the proteomics
histopathology of Grade IV.
An accurate tumor grade combining the phenotype and proteomics information,
following the latest standard of WHO tumor classification, provides a reliable diagnosis
and assessment of a brain tumor. This may help healthcare professionals to make good
treatment planning decisions.
The final dissertation goal is to propose a universal deep learning model for brain
tumor segmentation, tumor subtype classification, and overall patient survival prediction.
We propose a context-aware deep learning method for tumor segmentation, since the
context encoding module captures global context encoding features. The segmented
tumor is then used for tumor classification by utilizing a 3D CNN. Moreover, we also
propose a hybrid method for overall survival prediction. Specifically, we obtain highdimensional feature extraction, using the front-end of the CANet, and then we apply the
least absolute shrinkage and selection operator (LASSO) feature selection method to
these extracted features, and finally we implement an overall survival prediction method
based on the selected features.
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Brain tumor segmentation, tumor subtype classification, and overall patient survival
prediction are of importance for brain tumor analysis. With the capability of a deep
neural network, these brain tumor analysis steps are becoming more robust, which may
help the clinical outcomes for patients with a brain tumor.
The overall goals, novel contributions, and outcomes of this dissertation are
summarized in Table 20.
Table 20. Summary of novel contributions
Chapter Topic
3
A longitudinal
brain tumor
tracking using
feature and label
fusion

4

Contributions

• Exploited tumor
cell density as a
feature to predict
brain tumor
segmentation
prediction
• Improved the
performance of
another successful
tumor segmentation
method GB, by
fusing with RFbased segmentation
labels.
A deep
• Integrated
learning-based
cellularity
tumor grading
features from
method using
improving tumor
pathology and
grading
proteomics data • Discovered the
potential
correlation
between
cellularity and
IDH types.

Results
The proposed
pipeline shows
improved
longitudinal
brain tumor
tracking
compared to the
state-of-the-art.

Publications
Published two
conference
papers: [14, 15]
and one journal
paper [13]

The proposed
pipeline shows
the deep
learning-based
method for
tumor grading
having the stateof-the-art
performance

One journal
paper (under
review)
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5

A context-aware
deep learning
for brain tumor
segmentation,
subtype
classification
and overall
survival
prediction

• Proposed a
context-aware
deep learningbased method for
brain tumor
segmentation
• Utilized a hybrid
method for
overall survival
prediction
• Proposed a tumor
classification
using structural
MRI data only

The proposed
method shows a
competitive
performance on
tumor
segmentation,
promising
performance on
overall survival
prediction, and
state-of-the-art
on tumor
subtype
classification

One journal
paper (under
review)
One conference
paper published
in SPIE-Medical
Imaging
Won the 2nd
place in CPMRadPath
Challenge 2019

6.2 Future Works
Even though our proposed work either exceeds and/or reaches state-of-the-art
performance in the proposed goals, there is a lot of space for improvement. For the first
dissertation goal, we propose two methods for longitudinal brain tumor tracking, and the
performance of the experiment shows the state-of-the-art. To make the proposed
framework even more useful, we plan to extend the models for segmentation of other
abnormal tissues, such as the cysts and necrosis associated with brain tumor. A more
robust label fusion may help, for the second method to obtain improved longitudinal
tumor segmentation prediction. We further plan to improve the underlying feature
extraction, tumor growth, and segmentation models. A more comprehensive tumor
growth model development that also considers the treatment modalities may be
interesting.
For the second dissertation goal, we propose a deep learning-based method for tumor
grading by following the new WHO criterion. The experimental results show the
promising performance. However, this still has challenges. First, development of an
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automated method may be needed, since region of interest (ROI) selection from the WSI
is critical for the tasks. Second, we plan to repeat the proposed method and the
experiments using larger patient data, in order to validate the findings in this study for
improved tumor type and subtype classification.
For the final dissertation goal, we propose a deep learning-based method for multiple
tumor analysis tasks. These tasks are studied together, considering the underlying
relationship. Although the performances are good, especially for tumor segmentation and
tumor subtype classification, the performance on overall survival prediction is unstable,
due to the small number of cases in training. Therefore, we plan to increase the number of
patient cases to improve the performance. Furthermore, we will integrate the whole slide
image and the proteomics genetic features for tumor classification, following the new
WHO criterion.
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APPENDICES
APPENDIX A: ALL 30 FEATURES USED in OUR PROPOSED METHOD
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APPENDIX B: AVERAGE FALSE NEGATIVE RATE (FNR) AND FALSE
POSITIVE RATE (FPR) COMPARISON BETWEEN RESULT OF THE
PROPOSED METHOD AND BRATUMIA (BTIA)
Tumor type
FNR
FPR

WT
JLF
0.227
0.000889

BTIA
0.3426
0.000956

TC
JLF
0.2489
0.000344

EN
BTIA
0.3833
0.0006

JLF
0.1159
0.0009

BTIA
0.2698
0.000778
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